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ABSTRACT
Epidemiological evidence suggests that dietary fat may be an aetiological
factor for breast cancer. In this study the plasma lipid profile and
G\mlA}sfs iv\
prolactin on first presentation are compared witMbilScvwi^patients with 
benign breast disease.
When matched for menopausal status, the plasma concentration of 
total lipids, phospholipids, triglycerides, cholesterol, 3-lipoproteins and 
free fatty acids were higher in patients with cancer than in those with 
benign disease.
Patients with duct papilloma had plasma concentrations of total 
lipids, and total cholesterol that were higher than those of patients with 
other benign disease tu.t not significantly different from those of the 
cancer patients. In contrast, the concentration of triglycerides, and free 
fatty acids were lower than in cancer patients and similar to those in 
patients with other non-cancerous breast disease. It is suggested that 
these results support the view that lipids are associated with the 
development of breast cancer. This may be by aiding the retention in the 
body of carcinogen. It is also possible that the blood lipid profile is 
secondary to hormon changes which predispose certain women to develop 
breast cancer.
wilU omit*
The mean concentration of prolactin was higher in intklvmcds/v than in 
-VYvds^  vJHU
/'benign disease patients. In both groups prolactin levels were higher in pre- 
than in postmenopausal, patients. In cancer^but not in non-cancer patients, 
prolactin was positively correlated with total plasma lipid concentration 
after, but not before, the menopause. These relationships are discussed in 
relation to a possible link between prolactin, blood lipids and aetiology of 
breast cancer.
Human breast cancer is probably of multi factorial aetiology, and the 
present findings would be in agreement with /• involvement of dietary fat.
Immediately after surgery in the cancer patients there was a fall in 
the plasma concentration of total lipids, phospholipids, cholesterol $ - 
lipoproteins. During the same period there was a rise in the concentration 
of free fatty acids and HDL-cholesterol. Total lipids, phospholipids and 
triglycerides had regained their preoperative values by 28 days.
The orthopaedic surgery study was undertaken to assess the 
metabolic response to trauma in patients having either emergency surgery 
or elective surgery for femoral neck fractures. This study also provided 
data for comparison with that obtained in the breast cancer patient in 
order to make it possible to identify changes which are more likey to be of 
general occurrence^ rather than^ limited to occurring after mastectomy. 
Twenty-seven elderly patients who had undergone surgery to treat, a 
fractured neck of femur were included in the study. Blood samples were 
taken 48 hours, 7 days and 14 days postoperatively. A preoperative baseline 
sample was obtained in the elective surgery group.
Analysis of the plasma samples revealed a significant fall in the total 
lipids, total cholesterol and triglycerides in the immediate postoperative 
period in the elective surgery group. However, the concentration of HDL- 
cholesterol rose significantly during the same period. In the emergency 
group the HDL-cholesterol fell on the seventh day^but regained its pre- 
operative value by the second week.
The downward trend in total lipids, total cholesterol, and 
triglycerides, in the immediate post-operative period, may conceal a high
plasma lipid concentration prior to injury, so that the patient may not be
Luny
recognized as^hyperlipidaemic due to the lowering effect of the trauma.
The marked fall in the concentration of cholesterol was associated 
with trauma regardless of the pathological state of the patients.
V(CUXJ
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CHAPTER ONE
In tro d u c tio n
CHAPTER ONE 
METABOLIC STUDIES IN BREAST CANCER 
Literature Review
1.1 General Introduction
In 1900 pneumonia and influenza headed the list of the ten leading 
causes of death in the United States of America (U.S.A.) followed by 
tuberculosis, infectious gastrointestinal diseases and heart disease. Cancer 
was eighth and caused less than 4% of all deaths (Epstein, 1979). By 1976, 
cancer was the second leading cause of death after heart disease, 
accounting for about 20% of all deaths. Cancer is the only major killing 
disease whose incidence is on the increase. A baby born in the United
States today has in excess of one chance in four of developing cancer
of Hie pc-pviLh'on
during his or her lifetime and of the totalj approximately one-halfywill die 
of the disease (Kessler, 1980).
Cancer occurs not only in the elderly, but also in other age groups, 
including infants. Among males, cancer is the second leading cause of. 
death for all age groups except 15-34 years where it is exceeded by violent 
death, accidents, homicide, and suicide. Among females cancer is the 
leading cause of death for the ages 35-54 years and the second leading 
cause for all other ages up to 75. The most common sites of fatal cancer 
are the lung and large bowel in men, and the breast and large bowel in 
women. Leukaemia is the leading cancer in children.
Over 12000 women die of breast cancer every year in the United 
Kingdom (UK); in the U.S.A. the figure is 34,000 (Baum, 1981). It ranks as 
the commonest cancer in women and the commonest cause of death in the 
35-55 age group. Any individual woman in her life-time stands a 1 in 14 
chance of developing the disease, and there is even some evidence that the 
annual incidence and mortality rates are increasing throughout the Western 
Hemisphere. Because of these disturbing facts the subject has become
highly charged and emotional, so much so as to tend to cloud rational 
discussion.
Cancer of the breast has been recognized as an entity since the times 
of the ancient Egyptians. An early papyrus describes how it is 
differentiated from mastitis. No treatment was advocated other than 
cautery for ulcerated tumour. Surgery for breast cancer was practiced by 
ancient Greeks, but Hippocrates considered no treatment at all was 
superior to surgery : probably a very wise opinion in those days.
1.2 Epidemiological Studies and Dietary Fat Intake
The role of nutrition and diet in the causation and prevention of 
human cancer is a subject of great public anxiety. It is ironic that while 
the population of the industrial world is enjoying unprecedented health and 
longevity, there is prevailing concern that this technological society is 
placing upon them an intolerable burden of cancer.
Once it was noted that the risk of breast cancer varies according to 
geographical area, investigators began to consider environmental factors, 
such as diet, in the hope of explaining these regional variations.
Lea (1966) plotted per capita fat intake against age-adjusted death 
rates from breast cancer for 24 countries and found a highly significant 
positive correlation (P < 0.001) between fat intake and death rate of breast 
cancer in women over 55 years old in these countries.
In a study of 37 countries, Drasar and Irving (1973) found a 
(r)
correlation of 0.8 between breast cancer incidence and per capita intake of 
total fat.
Armstrong and Doll (1975) correlated, breast cancer incidence from 
23 countries and mortality from 32 countries of persons 35 to 64 years old, 
with dietary and other environmental variables. They reported correlations 
of 0.89 between breast cancer mortality rate and per capita fat intake. 
However, this study also showed that breast cancer incidence was better 
correlated to gross national product c r = 0.83) than to total fat 
consumption ( r= 0.79). This underlines the fact that the question of a 
causal relationship has to be considered with care.
Carrol and Khor (1975) related breast cancer mortality data to total 
fat intake for 40 countries. They found a significant positive correlation 
( r= 0.935) between total fat intake and death due to breast cancer. The
correlation between animal fat intake with breast cancer mortality was not 
as high as that with total fat, and intake of vegetable fat showed little, if 
any, correlation. Vegetable fat may be expected to be, if anything, more 
unsaturated than animal fat although some plant fats such as coconut oil 
are relatively saturated and others may be partially hydrogenated for 
edible use. This classification, cannot therefore be used as a reliable guide 
to possible differences between effects of saturated and unsaturated fats 
in humans.
Hirayama (1978) showed a highly positive correlation between per 
capita fat intake and adjusted death rates from breast cancer in different 
districts of Japan. He suggested that the breast cancer death rate will rise 
to the U.S.A. level when Japanese dietary fat intake approaches present 
day U.S.A. levels. The close correlation with fat intake was noted to come 
mainly from the consumption of pork and animal fat. The ratio of recent 
increase in breast cancer death rates was also found to be under the 
combined influence of animal fat and 'AF21, a highly mutagenic food 
additive widely used in Japan from 1965 to 1975,and shown to produce 
mammary carcinoma in rats.
Gray et al., (1979) correlated breast cancer incidence and mortality 
rates in 34 countries with total fat consumption per capita. Even after 
controlling for height, weight and age at menarche they found that the 
incidence rate was highly correlated with total fat intake (R = 0.78).
Recently, Lubin et al., (1981) carried out a case-control study in 
Northern Alberta, Canada, on 577 women aged 30-80 with breast cancer 
diagnosed during 1976-77 and a population-based age stratified random
sample of 826 disease-free female controls. The women were questioned 
about certain aspects of their diet and the relative risks compared by 
tertiles, significantly increasing risks were found with more frequent 
consumption of beef ( P< 0.001), pork ( P< 0.001) and sweet desserts ( P<
0.01). The results may have been influenced by case recall bias for it is 
likely that women with breast cancer would selectively remember certain 
dietary items (beef and pork) and not others, as compared to controls.
A pilot study based at the Jarvis Screening Centre, Guildford, 
emphasized the inherent limitations of case-control surveys of dietary 
patterns associated with chronic diseases (Cutler, 1980). A "Daily Fat 
Score" derived from a dietary history was used to estimate the total fat 
intake of all subjects. Fat scores and the consumption of milk and other 
foods were compared for cases and controls. In all calculations, the mean 
values of patients and controls were very similar and without significant 
difference. The higher "daily fat score" of patients was weakly significant 
(0.1 < p < 0 .20) as was their higher consumption of butter, cream, eggs and 
margarine.
Several reviews of risk factors associated with breast cancer have 
been published (Wynder, 1969; MacMahon et al., 1973). Relationships of the 
disease with age, geographical residence, socioeconomic status, family 
history, lactation, previous benign tumours, ages of menarche and 
menopause, reproductive experience and obesity have been reported. 
Reproductive history, endocrine status and diet are currently thought to be 
the three principal factors implicated in the development of breast cancer. 
In addition, for women developing breast cancer before menopause, the 
family history may be relevant.
In areas of high risk, namely North America and N.W. Europe, 
MacMahon et al., (1973) showed that risk increases with age throughout 
life. In low risk countries of Asia and Africa, risk increases until middle 
age and then decreases. This variation between low and high risk 
countries may indicate a difference in exposure to aetiological agents in 
the environment.
About two decades ago, it was widely believed that malignant 
neoplastic disease was rare among Africans. However, the introduction of 
cancer registeries in many centres and the progressive documentation of 
cases has shown this belief to be wrong. For instance, cancer deaths in 
Kenya account for as much as 20% of the overall mortality in adults and 
9% of that in children (Kasili, 1983). The situation is likely to be much the 
same in other countries of sub-Saharan Africa.
In the Sudan, breast carcinoma forms 29.7 per-cent of all tumours in 
the female (Daoud et al., 1967). In the Sudan, North of the Southern 
provinces, breast cancer is, by a wide margin, the most frequently recorded 
malignant tumour. Hickey (1959) comments that it "is the commonest 
single cancer seen in our laboratories". Considering the local conditions it 
is almost certain that it must be the commonest in the Sudan, due to the 
high consumption of meat in the diet.
It is commonly believed that the low incidence of breast cancer in 
Africa is due to prolonged lactation and the high birth rate and this applies 
to the Sudan where the mean parity is about four children and breast 
feeding is continued for 18 to 24 months. In the Muslim community of the 
Northern Sudan, prolonged lactation may have resulted from the influence 
of the Koran which states "and his weaning is two years" (Sura 31, verse 14). 
Breast cancer in the male is relatively more common amongst Africans.
Nine and 3.5 percent of Nigerians and Sudanese patients respectively with
N o /tk
breast cancer are males which is higher than in Europe and^America (Daoud 
et al., 1967; Khwaja et al., 1980). This is thought to be the result of 
hyperoestrogenism associated with liver disease and gynaecomastia both of 
which are common in Africa (El Gazeyerli and Abed Alaziz, 1963).
The overall mortality rate from breast cancer has shown little  
improvement since the turn of the century (Thomas, 1979). The aetiology,
f’volocAsl'j *<xL
i multifacViK , is sufficiently obscure that rational approaches to
the prevention have not yet been possible. In spite of all the techniques 
now available for the treatment of breast cancer, the overall survival rate 
is still low (Priestman et al., 1978). Further investigations into the 
aetiology of breast cancer are essential if preventive measures leading to a 
reduction in mortality rate are to be discovered.
1.3 Experimental studies and dietary fat intake
Through the efforts of Tannenbaum (1942), the field of nutritional
carcinogenesis experienced a burst of creative activity in the early 1940's.
In 1967, interest in this field was regenerated with publications by Carrol
and co-workers of nutritional studies using the 7,12-
dimethylbenz(a)anthracene (DMBA) mammary tumour model (Carrol, 1975). 
t\v\A Silveys+one
Tannenbuam /  early work (1957) brought to light four major facts 
concerning the relationship of dietary fat to breast cancer, facts which are 
of compelling interest today:
1. The quantity of dietary fat, holding carbohydrate and protein constant, 
influenced the subsequent development of mammary cancer ;
2. The time of initiation of the diet influenced the course of tumour 
development;
3. The reproductive history of the animals was an important experimental 
variable;
4. Caloric restriction has a profound retarding effect on the genesis of 
mammary tumours, as well as tumours at other sites.
Using the DMBA model, Carrol and Khor (1971, 1975) studied the 
effect of a variety of fats and oils on breast cancer development. When 
tumour incidence was the end point measured, high fat diets promoted 
tumour development in most but not all the experiments. Another aspect 
of the high fat effect on breast carcinogenesis is the finding in both the 
DMBA model and the transplantable mouse mammary tumour, that the 
tumorigenic response to fat intake is not linear in nature. When the corn 
oil content of the diet was increased from 5 to 20%, a significant 
difference in tumour incidence occurred. However, increasing dietary fat 
above 20% or decreasing it below 5% had no discernible effect on tumour 
incidence.
To summarize, five major themes emerge from this survey of 
experimental studies on dietary fat and carcinogenesis.
1. Dietary fat exerts its effects on the promotional phase of breast 
carcinogenesis.
2. Promoting agents, such as excess dietary fat, play a more significant 
role in determining the eventual outcome of the neoplastic process 
when the initiating carcinogen dose is low than when it is high.
3. The total quantity of dietary fat, irrespective of qualitative factors,
is a central factor in the high fat effect.
.4. A certain threshold quantity of essential fatty acids that is more than
2% of the total fat, is a necessary requirement for full expression of
the high fat effect.
C
5. The response to dietary fat consumption is saltatory, or
discontinuous, rather than linear or graduated, in nature.
Postulated mechanisms by which dietary fat may influence breast 
cancer fall into two basic categories, namely, those involving direct 
effects of fat on tumour development and those involving indirect effects 
on host metabolism (Cohen, 1981). Direct effects involve changes in (a) the 
lipid content of the ceil membrane and (b) the synthesis of prostaglandins. 
Indirect mechanisms involve (a) subversion of the immune systems, (b) 
stimulation of mixed-function oxidase systems involved in carcinogen 
activations (c) alterations in faecal flora and bile acid metabolism (d) 
alterations in the endocrine state of the host. Biological mechanisms by 
which dietary fat may exert effects on breast cancer, (the overlapping 
circles - solid areas) indicate that no single mechanism is mutually 
exclusive of any other mechanism (Fig 1 • 1) •
DIETARY FAT
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Figure 1.1 :
Postulated mechanisms by which dietary fa t may influence breast cancer,
Ref: Cohen, 1^81.
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The role of adipose tissue in breast carcinogenesis either acting as a 
reservoir or depot for carcinogens has been a regularly reappearing 
theme over the past 30 years. The abundant adipose tissue that intimately 
invests both the alveolar and the ductal epithelium of the mammary gland 
may function as a slow-release depot for lipid-soluble carcinogenic agents 
of both endogenous and exogenous origin taken up from the blood stream 
(Beer and Gillingham, 1978).
Since polyunsaturated fatty acids (PUFA) are converted by free 
radical reactions to lipid peroxides, a model involving breast cancer and 
lipid peroxidation has been advanced. It is possible that increased 
peroxidation of membrane lipids results in alteration in the function of 
transformed mammary cell membranes which, in turn, permits increased 
rates of growth (Hopkins and West, 1976).
Lipotropes (choline, methionine, folic acid, and vitamin Bj^) are
required for normal metabolic function at cellular and subcellular levels.
Deficiencies of any or all of them, to a point at which they influence
methyl group metabolism, has a profound effect on synthesis of cellular
macromolecules and on cell proliferation. Lipotrope deficiency results in
diminished immunocompetence and increased susceptibility to a number of
types of cancer in experimental animals (Newberne et al., 1983).
Lipotropes are nutrients that are significant in fat metabolism \and also
Is _.influence carcinogenesis in experimental animal mode Dietary
deficiency of lipotropes enhances susceptibility of the liver of rats to many 
carcinogen s. The deficiency alters xenobiotic metabolism and increases 
cell divisions' in the liver. There appear to be interactions between dietary 
lipid and lipotropes that influence carcinogenesis, but they have not been 
adequately studied (Rogers, 1983).
1.4 Lipid Metabolism in Breast Cancer
As stated, leads established by epidemiological studies and tested in 
animal models must be confirmed in the human setting. There is a 
substantial but not well integrated body of information concerning the lipid 
content of human tumours. A more complete study concerning lipid content 
in breast tumours was submitted more recently by H ilf et al., (1970). They 
reported that the contents of cholesterol, cholesterol esters, and free fatty  
acids showed statistically significant increase in carcinoma, and the 
content of triglycerides showed a marked and significant decrease 
compared with normal breast tissue and fibrocystic disease.
Changes in the concentration of various lipid components in the 
serum or plasma of patients with cancer have been reported for many years 
(Bloor, 1916; Mattick and Buchwald, 1929). The latter investigators reported 
raised plasma total fatty acid and cholesterol concentrations in cancer 
compared with normal individuals, although no statistical evaluation was 
done. Tlvis study did not take into account a number of factors, such as 
clinical status, age, and sex of the patients, which might influence the 
results.
Barclay et al.,(1955) reported lower levels of plasma alpha-lipoprotein 
in patients with breast cancer than in normal women of the same age 
range. The concentration of plasma $-lipoprotein was essentially the same 
in both groups. The changes in the serum lipoprotein pattern of patients 
with carcinoma of the breast have been generally, but not completely, 
confirmed by other workers. Using filter paper electrophoresis, Miller and 
Erf (1956) reported that the concentration of a-lipoprotein was decreased 
but, in contrast to the findings of Barclay et al., (1955), that of $- 
lipoprotein was increased in patients with advanced carcinoma of the 
breast. In a comprehensive survey of lipoprotein and other plasma lipids in 
women with metastatic carcinoma of the breast who were post menopausal
or had undergone radiation or surgical castration, Feldman and Carter 
(1971) have shown that the concentrations of plasma free fatty acids were 
significantly higher, and the concentrations of cholesterol significantly 
lower than in a control group of healthy post-menopausal women. In 
contrast to the results of Barclay et al., (1955) and of Miller and Erf (1956) 
there was no alteration in the level of a-lipoprotein.
Tumours require lipid for membrane synthesis to proceed at a 
sufficient rate to permit rapid growth (Spector and Brenneman, 1973). A 
fundamental question in this regard is whether tumours synthesize de novo 
the lipids that they need or obtain them preformed from the host. This is a 
crucial point in terms of chemotherapy that might eventually be directed 
against lipid metabolism. Tumour growth undoubtedly would be prevented 
or slowed if the availability of lipids could be sufficiently reduced.
Great caution must be exercised in drawing conclusions from all 
three types of studies mentioned here. Epidemiological studies use crude 
data derived from the food balance sheets of Food and Agricultural 
Organisations of the United Nations. This data can only reflect amounts of 
food available per person and the quantities consumed. It does not show 
the distribution of food by sex and age within the different countries. 
Similarily, the data for breast cancer mortality, although adjusted for age, 
may be influenced by factors such as the standards of health care and the 
frequency of other disease processes. The heterogenous nature of the 
population in many countries also increases the difficulty of interpretation.
- 14 -
Results from rodent experiments are of interest but should not be 
extrapolated directly to human populations. Although the disease in rats 
may be similar to that in humans, there are differences in susceptibility 
between species.
Of the the three types of studies, human case-control studies are 
undoubtedly the best tool with which to investigate the aetiology of breast 
cancer with respect to diet. The selection of suitable controls is probably 
the only major limitation.
1.5 Pathology of Breast Diseases
The commonest benign diseases of the breast are shown below :
Fibroadenoma 
Lipoma
Duct Papilloma 
Skin lesions 
Fibrocystic disease 
Fibroadenosis 
Solitary cysts 
Puerperal abscess 
Periductal (plasma cell) mastitis 
Tuberculosis 
Haematoma 
Fat necrosis 
Supernumerary breast 
Absent breast 
Asymmetrical development
Benign neoplasia
Dysplasia
Inflammatory disease
Trauma
Developmental
Girls of 15-25 years of age may consult their doctor about a well 
defined lump which on pathological examination is nearly always found to 
be a fibroadenoma. Duct papillomas are little  warty growths that occur 
within lactiferous ducts. The first symptom is a bloody or yellow discharge 
from the nipple. They can occur at all ages and should be removed, partly 
because of their nuisance value and partly because on rare occasions they 
have malignant potential (Baum, 1981).
It is important to divide cancer of the breast into different histological 
types. When these types can be identified, they may offer a basis for 
predicting the probability of metastasis, the choice of treatment and the 
prognosis.
The following classification is that proposed by Baum (1981) :
Duct origin Pre-invasive Intraduct cancer
Invasive Invasive duct cancer
Rare sub-types
Tubular
Mucinous
Medullary
Lobule orgin Pre-invasive
in'
lobular carcinoma f situ
Invasive lobular invasive carcinoma
Connective tissue origin sarcoma (rare)
1.6 Diagnosis of Breast Cancer
The successful treatment of carcinoma of the breast depends, to a 
considerable extent, on early diagnosis, yet in spite of public education and 
a great desire on the part of modern women to seek medical advice, a large 
proportion of carcinomas diagnosed today already have progressed beyond 
the site of origin in the mammary gland.
A woman who discovers a lump in her breast or abnormal nipple 
discharge usually visits her own doctor. Theresa clinical diagnosis will be 
carried out involving a full history into the family background, social 
habits, occupation, and preceding signs and symptoms prompting the 
patient to seek advice. A thorough examination of the patient is then 
performed, with palpation of the tumour if  it is accessible. Special 
diagnostic facilities such as mammography and xerography, are available in 
some hospitals and breast clinics.
1.6.1 Staging of breast cancer :
Clinical staging of carcinoma of the breast is of relative value for 
planning and management of the disease. The TNM classification (for 
explanation of the letters TNM see below), of breast cancer is a method of 
describing the extension of the disease on the basis of clinical findings. It 
should enable a proper choice of therapy to be made, by comparing the 
results of patients in the same category receiving different types of 
treatment.
•fciovvcA.
The TNM systems was devised by the Interna ^Union Against Cancer 
(UICC),to provide a common international language for characterising 
breast tumours. The letters TNM designate :
T = the clinical extension of the primary tumour,
N = the clinical appearance of adenopathy ,
M = the existence or not of distant metastasis.
Each category is subdivided into Tj and T2    Ng, Nj etc. The following
TNM categories have been described for breast cancer.
T Primary Tumour
Tg No evidence of primary tumour
T^ Tumour 2cm or less in greatest dimension. Skin not involved, except
in the case of Paget's disease.
Confined to the nipple.
No retraction of the nipple.
No pectoral muscle fixation.
No chest wall fixation.
T2  Tumour more than 2cm but not more than 5cm in greatest dimensions
or incomplete skin fixation (tethered or dimpled), or nipple retraction 
(in subareolar tumours), or Paget's disease extending beyond the 
nipple.
No pectoral muscle fixation.
No chest wall fixation.
T j  Tumour more than 5cm but not more than 10cm in greatest
dimensions, or skin fixation complete (infiltration or ulcerated) peau 
d'orange in tumour area, or pectoral muscle fixation (incomplete or 
complete).
No chest wall fixation.
T^ Tumour more than 10cm in greatest dimension, skin involvement or
peau d'orange wide of tumour but not yet beyond breast area, or 
chest wall fixation.
-xo  -
N Regional Lymph nodes.
The clinician may record whether palpable nodes are considered to 
contain growth or not.
Ng No palpable homolateral axillary nodes.
N^ Movable homolateral axillary nodes.
N ja  nodes considered not to contain growth.
N ^  nodes considered to contain growth.
N2  Homolateral axillary nodes fixed to one another or to other 
structures.
N^ Homolateral supra- or infra-clavicular nodes, movable or fixed, or 
oedema 0 ,J the arm.
M Distant metastas is .
Mg No evidence of distant metastases.
M^ Distant metastases present.
M, skin involvement wide of breast, la
M ^ involvement of contralateral nodes or contralateral breast.
Mjc clinical or radiological evidence of metastases to lungs, pleural 
cavity,skeleton, liver, etc.
Other classifications of breast cancer are based on histological evidence.
1.6.2 Outpatient biopsy :
If test aspiration demonstrates that the discrete lump is in fact solid, 
then ideally an attempt should be made there and then to get histological 
confirmation of the diagnosis. There are two methods that have to be 
considered. First, cutting needle biopsy and, secondly, aspiration cytology.
1.6.3 Mammography :
Mammography involves a soft tissue x-ray of the breasts. 
Carcinomas as small as 0.5cm can be demonstrated. Tiny calcified flecks 
seen on a mammogram are strongly indicative of breast cancer. Care has 
to be taken, especially in women under 50 years, and mammography does 
use x-rays.
1,6.b Xerography :
In xerography an electrostatically charged selenium coated plate is 
used instead of an x-ray film. The completed print is a positive in blue and 
white, with well defined edges and clear detail. Lesions as small as 2 mm 
can be detected, and therefore it has considerable potential for early 
diagnosis of breast cancer.
1.6.5 Thermography:
In thermography an infra-red camera is used and the varying 
temperatures over an area recorded on a photograph. The breast region 
has first to be cooled for about 20 minutes, by removing the clothes from 
the upper half of the body. This is to reduce the risk of obtaining a false 
positive result. If  a cancerous area is present it will be at a higher 
temperature than the surrounding tissue, and will be seen as a black area 
on the picture. The advantage of thermography is that it is quite safe, 
although it is not as accurate as mammography or xerography.
1.6.6 Screening :
A screening programme for the earlier detection of breast cancer 
offers potential for an improvement in survival rates. A combination of 
clinical examination and low-dose mammography offers the most reliable 
method of screening at the present time (Gleave, 1977). The two 
investigations are essentially complementary to each other, since clinical 
examination loses accuracy in the largest breast and mammography is less 
satisfactory in technical terms for the small breast. It has been found that 
groups of women with carcinoma of the breast found on screening have 
one-third fewer deaths^than a group of controls with cancer of the breast 
(del Regato and Spjut, 1977).
1.6.7 Roentgenologic Survey :
A routine roentgenogram of the chest is advisable in all patients with 
breast cancer on first examination and, of course, periodically following 
treatment. Pulmonary metastases from carcinoma may be found on lung 
fields, a long time before any symptom betrays their presence.
1.6. 8 Scintigraphy :
Bone scans using radionuclides have proved more sensitive in 
detecting asymptomatic skeletal metastases than have roentgenographic 
bone surveys.
1.7 Treatment of Breast Cancer
The treatment of breast cancer combines a whole spectrum of
surgery, radiotherapy, chemotherapy, hormone therapy, and
of
immunotherapy. Surgery can involve removal of the breast,^ endocrine 
organ ablation such as adrenolectomy, hypophysectomy, and oophorectomy.
Three types of mastectomy, depending on the initial clinical form, 
involvement of pectoral muscles and lymph nodes, are commonly carried 
out for breast cancer.
1. The Halstead radical mastectomy involves the removal of the whole 
breast, pectoral muscles and dissection of all the axillary nodes. A supra 
radical mastectomy may include a dissection of the internal mammary 
glands and supraclavicular glands as well.
2. In the Patey mastectomy the breast and the axillary nodes are removed, 
leaving the pectoral muscles intact.
3. The simple mastectomy involves the removal of the bulk of breast 
tissuesy Jvt/v local axillary node dissection may be carried out.
It is possible, by skilful use of radiation, to destroy carcinoma in the
breast and in metastatic foci. This fact has been amply verified.
Preoperative radiotherapy has long been practiced and studied (Delarne et
al., 1963 and Fletcher et al., 1968) but has never gained many advocates.
Postoperative radiotherapy is often used to remedy the unavoidable
proportion of local and regional recurrences that result after the most
skillful surgery. The purpose of post operative radiotherapy would be to
destroy tumours that might have been left just beyond the area of/% the
■ to o d  v i f c v d A  I v x v j e .
surgical field x w  1 or/vSpilled irtthe surgical field at operation ; the 
first of these is the Move important consideration.
A great deal of information is available on the effect of hormones on 
the control of breast cancer growth. It is normal to divide patients into 
pre-menopausal (including up to 2 years after the last menstrual period) 
and postmenopausal. The type of therapy depends on the menopausal 
status.
In the pre-menopausal patients the main objective is to remove the
by
source of oestrogens or to modify their effects/* using androgens. 
Therefore, oophorectomy, surgically performed or radiotherapeutically 
induced, is an effective method of treatment, a response occuting in 
approximately 25% of all patients (Caiman et al., 1980). Prediction of this 
response Can be made accurately by measurement of the oestrogen 
receptor status. Following response to such procedures, a second remission 
may be induced by adrenalectomy or hypophysectomy. Alternatively, 
androgenic steroids may be used, and several forms are commercially 
available. Aminoglutethimide, which inhibits steroid synthesis in the 
adrenal gland, may also be used for this purpose.
Postmenopausal patients have low oestrogen levels and the tumour is 
often responsive to administration of oestrogens. The synthetic hormone, 
Stilboestrol, has been most frequently used in the past, but a new range of 
compounds that are oestrogen analogues, including Tamoxifen and 
Nafoxide, have been recently introduced with good results. These have 
now largely replaced the use of Stilboestrol. Corticosteroids also have a 
place in the management of breast cancer^ both in combination with 
chemotherapy, and in the management of complications such as 
hypercalcaemia.
Much current interest has been generated by the new group of drugs 
referred to as antioestrogens, of which Tamoxifen (Nolvadex) is perhaps 
the most effective and least toxic. This drug works by competing for the 
binding site on the oest radiol receptor.
Chemotherapeutic drugs act by disrupting the mitotic cycle of the 
cell, and death follows. This occurs either by changing an essential 
element in cell division, which is usually a nucleic acid, or by inhibiting the 
synthesis of this element at various stages of its function in vivo. Nitrogen 
mustards such as Karyolysin and Endoxana are examples of the first group, 
Methotrexate and 5-fluor  ^4acil are examples of antimetabolites.
The development of immunotherapy is opening another method of 
treating cancer. The general principle is that the cancer cell is destroyed
following the formation of antibodies by the host. The antibodies are
<-! tViSY
humoral or cellular v and are directed against the antigens
belonging to the malignant cell.
It is outside the scope of this study to describe in detail all the 
techniques belonging to the different disciplines, but it has to be 
remembered that each patient will require a combination of several 
techniques. Any increase in the chance of cure is likely to arise from the 
combination of these treatments.
1 .8 Hormones and Breast Cancer
1.8.1 Introduction:
Cancer of the breast is best described as hormone-dependent on the 
basis of two findings:
(a) it arises from tissues that are normally responsive to endogenous
hormones and, .
eAtKo.v'
(b) its course can often be influenced, favourably or unfavourably,Aby 
administration of hormonespor removal of hormones (by surgical or 
radiation ablation of endocrine glands*, or by administration of 
antihormones).
The basic methodology for studying the role of hormones in hormone- 
dependent cancer is what might be called "biochemical epidemiology" i.e., 
a cross-sectional study of hormone differences between subjects with and 
those without a particular type of cancer. The potential relationship of 
some hormonal patterns to^breast cancer in humans suggests that
diet or nutritional status may function as modifiers of mammary 
; C(kv\c^ v (Hankin and Rawlings, 1978). The following review is 
limited to selected hormonal hypotheses which may have dietary 
implications.
1.8.2 Oestrogens : -
A positive aetiological role for oestrogens in human breast cancer is 
suggested by evidence for involvement of some feature of ovarian activity, 
by a vast amount of work on animals, and by the clinical response of many 
human tumours to either oestrogens or their antagonists. Women produce 
substantial amounts of three major oestrogens : oestrone (Ej), oestradiol 
(E2 ) and oestriol (E^). During pregnancy, the total oestrogen secretion 
rises considerably, with E  ^ increased to a far great extent than E^ or E2 . 
This is of interest because of the reduced risk of breast cancer associated 
with early pregnancy.
Cole and MacMahon (1969) have suggested that may have lower 
carcinogenic potential than the other oestrogens and proposed that young 
women with a low ratio of Ej to E2  and Ej are at high risk of being 
affected by the disease. Earlier, Lemon et al., (1966) reported that 
premenopausal breast cancer patients exhibited reduced oestriol (E^) 
excretion rates compared matched controls. Stated briefly, the oestriol 
hypothesis holds that the risk for breast cancer is inversely proportional to 
the ratio of urinary E  ^ to Ej and E2  (Lemon, 1976).
Interest in the measurement of urinary oestrogens in breast cancer is 
based on the widely held presumption that oestrogens are carcinogenic with 
respect to the breast. This presumption, in turn, is based on the results of 
animal experiments and on human epidemiological data as follows : -
1. Of the 3 "classical" oestrogens of human urine, oestrone (Ej) and 
oestradiol (E2 ) cause breast cancer in rodents (Silberberg and 
Silberberg, 1938) and oestriol (E^) does not (Hartwell, 1938).
2. Human females castrated prior to their late 30*s have been shown to 
have about an 80% decrease in the incidence of breast cancer, no 
such decrease occurs in women castrated at a later age (Feinleib, 
1958). This has been generally interpreted to support the conclusion 
that oestrogens are carcinogenic to the human breast (Cole and 
MacMahon, 1969).
A study by Bulbrook et al., (1976) among healthy British women at 
high risk and Japanese at low risk revealed the inconsistency between 
plasma and urinary oestrogen values. Although plasma levels of Ej and E2  
in the luteal phase were higher in the Japanese adolescents than in the 
British girls, there were no plasma differences between British and
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Japanese premenopausal, menopausal and postmenopausal adults. Urinary 
oestriol (E^) ratios were somewhat higher in Japanese than in British 
adolescents and premenopausal women, whereas there was no difference in 
the older women. It is suggested that (MacMahon et al., 1973) urinary 
levels give a more sensitive index of production than plasma 
concentrations, which show marked short term fluctuations.
There is a positive correlation between the amount of oestrogen 
receptors (ER) in a mammary carcinoma and its probability of response to 
endocrine therapy (McGuire, 1975). Determination of ER levels in breast 
cancer is therefore a routinely performed analysis in many oncological 
centres (Silversward et al., 1980). Success rates of endocrine therapy in 
ER-rich tumours generally reach 60% (McGuire et al., 1977).
It is now generally appreciated that ER are found in 50 to 80% of 
human breast cancers and that 55 to 60% of ER + tumours are likely to 
regress following endocrine therapy, whereas those tumours lacking ER 
usually fail to respond as the response rate is 0 - 10% (Matsumoto and 
Sugano, 1978). There is no doubt that ER determinations are helpful in 
selecting patients with metastatic breast cancer for endocrine treatment.
There is a need for data relating dietary factors to the synthesis and 
metabolism of oestrogens. It is possible that the production of oestrone in 
fat tissues is greater among obese postmenopausal women than women of 
normal weight (Lipsett, 1975). Obesity may increase plasma oestrone by 
two mechanisms, a higher rate of secretion of oestrone precursor 
androstenedione, and a higher rate of conversion of androstenedione to 
oestrone. Thus, one may construct the sequence : obesity — } increased 
conversion of androstenedione to oestrone — ^increased plasma 
oestrone— ^promoter effects — abreast cancer. There are large gaps in 
our scientific knowledge concerning effects of diet on hormone synthesis 
and metabolism.
Because most nutrients participate in the citric acid cycle, and acetate is 
the primary precursor of all steroids, the potential interaction between 
diet, androgens, oestrogens, and prolactin is great (Harper and Grodsky, 
1979).
1.8.3 Progesterone :
Progesterone is one of the steroid hormones that influences 
differentiation, development and functions of the mammary gland. 
Progesterone has been considered both a mammary co-carcinogen (Poel, 
1968) and a protective agent by virtue of its ability to oppose oestrogen 
activity. The little information relevant to women is conflicting. 
Grattarola (1964) found that young patients with breast cancer have a 
higher frequency of anovular cycles than do normal women. Furthermore, 
he reported that 66% of married women with breast cancer had a history of 
primary or secondary infertility. Since anovular cycles are associated with 
reduced progesterone production a protective role for the hormone is 
suggested. Countering the suggestion that progesterone may be protective 
against breast cancer is the observation that oophorectomy, which virtually 
terminates progesterone production, lowers breast cancer risk. Thus, a 
place for progesterone in the aetiology of breast cancer is supported 
neither by direct observations nor by capacity to explain the known 
features of the epidemiology of the disease.
1.8.4 Androgens :
The two hormones dehydroisoandrosterone and dehydroisondrosterone 
sulphate are the major secreted "adrenal androgens" and they are 
quantitatively the major sources of urinary 17-ketosteroids, specifically 
androsterone, aetiocholanolone and dehydroisoandrosterone. 
Pharmacological doses of androgens have been shown to induce regression
of DMBA-induced mammary carcinomas of rat (Young et al., 1965) as well 
as human mammary carcinomas (Goldenberg et al., 1975).
Bulbrook et al., (1962) found that a low urinary excretion of androgen 
metabolites is associated with breast cancer. They suggested that low 
values might precede clinical symptoms of the disease. When international 
comparisons were made, the relationship between subnormal androgen 
metabolite excretion and increased risk for breast cancer did not confirm 
Bulbrook’s suggestions. Healthy British women (high risk) exhibited higher, 
rather than lower, urinary 17-ketosteroid excretion rates than healthy 
Japanese women (low risk) (Bulbrook and Hayward, 1967 ; Hayward et al., 
1978).
In the light of the conflicting results obtained from urinary and 
plasma androgen metabolite studies and the absence of information 
concerning the physiological role of androgens in breast carcinogenesis, the 
idea that the risk of breast cancer is a direct result of adrenal dysfunction 
must be regarded with caution.
Nonetheless, since changes in androgen metabolism are commonly 
found in high risk groups, one cannot entirely exclude on the basis of 
present evidence a role for androgens in the aetiology of breast cancer.
1.8.5 Prolactin :
1.8.5.1 Introduction:
Prolactin is the lactogenic hormone, whose main action is to initiate 
and sustain lactation. It is a simple protein with some chemical 
similarities to growth hormone but is a slightly larger molecule. Prolactin 
can induce milk secretion in cultured breast tissue from rabbits and this 
has been used as a bioassay for the hormone. Specific radioimmunoassays 
for prolactin which differentiate it clearly from growth hormone^are now
generally available and are used clinically. The secretion of prolactin is 
normally kept under tonic inhibition by secretion of a prolactin inhibitory 
factor (PIF). Cessation of the secretion of prolactin inhibitory factor 
allows prolactin secretion. Dopamine acts directly on prolactin secreting 
cells to inhibit secretion of prolactin. Although precise values differ 
between laboratories, serum prolactin levels are generally less than 400 
mU/t (20 ng/ml) in the morning and levels tend to be slightly higher in 
women than in men (Hall et al., 1981).
Hyperprolactinaemia may occur as an accompaniment of drug
therapy with dopamine receptor blocking drugs or dopamine-depleting
drugs and with oestrogens or thyrotrophin releasing hormone (Thorner,
1977). Oestrogens have a dual and possibly triple effect in stimulating
prolactin secretion. They deplete hypothalamic PIF (Prolactin Inhibitory 
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Factor) and/stimulate the prolactin-secreting pituitary cells directly. 
There is some evidence that they may act via releasing or synthesis- 
stimulating factors as well. The tricyclic antidepressents imipramine and 
imitriptyline both elevate plasma prolactin levels in man. All the 
phenothiazines tested including chlorpromazine, promazine, perphenazine, 
fluphenazine and thioridazine have been reported to stimulate prolactin 
secretion. L-dopa, which is a precursor of both dopamine and 
non adrenaline, elevates PIF secretion and reduces prolactin secretion. 
Sleep, stress, nipple stimulation, coitus, pregnancy and suckling are all 
associated with physiological hyperprolactinaemia.
1.8.5.2 Prolactin and mammary carcinogenesis
Considerable experimental work in mice and rats indicates that 
prolactin is an important hormone in the genesis of mammary cancer, 
acting most probably as a promoter or cocarcinogen (Pearson et al., 1969 ; 
Meites, 1972). In rats with mammary tumours induced by 
dimethylbenzanth racene (DMBA) the administration of prolactin 
decreases the latent period of the appearance of tumours and increases the 
incidence and growth rate of tumours. The administration of prolactin also 
leads to the recurrence of hormone-responsive tumours that have regressed 
as the result of oophrectomy, adrenalectomy, or hypophysectomy. When 
endogenous prolactin levels are increased as the result of fcsVw» v\ i S'VclY IW < 
chlorpromazine, the incidence and growth of mammary tumours are 
increased. Conversely, when pituitary prolactin secretion is decreased 
with ergot drugs, the incidence of DMBA-induced tumours and that of 
spontaneous mammary tumours are also decreased (Yanai and Nagasawa, 
1971).
1.8.5.3 Prolactin in Human Breast Cancer
There is much active work going on at present to explore the role of
prolactin in human breast cancer. Evidence for the role of prolactin in
human breast cancer is largely indirect and definitive proof of prolactin
dependency in human breast cancer has not yet been demonstrated.
Nonetheless, indirect evidence from comparison of Japanese and U.S. white
women suggest that prolactin plays a role in breast cancer. The results of
a study by Hill et al., (1976) in postmenopausal women showed a clear
elevation of prolactin levels in U.S. white and Japanese breast cancer 
ioUck
patients^ but not in/vSouth African i / . Ccmce/ patients when
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compared controls.
Let us examine critically the evidence for prolactin having a 
significant role in human breast cancer. It has been found that some 
families with - multiple cases of breast cancer have elevated 
circulating prolactin levels (Montague, 1977). It was also found that 
relatives of breast cancer patients have poorly functioning regulatory 
mechanisms of prolactin release. In some series (eg., Rolandi et al., 1974) 
high prolactin levels were found in patients with advanced breast cancer. 
Berle and Voigt (1972) reported that more cancer patients than normal 
controls had "measurable levels" of prolactin, implying that prolactin 
concentrations were higher in the cancer patients and this was true in all 
age ranges. In a further study, McFadyen et al., (1976) reported slight 
elevation of prolactin in 5 patients with breast cancer, but the difference 
was not statistically significant. Hobbs and associates (1974) reported the 
presence of prolactin receptors in human breast cancer cells and that 30% 
of breast cancer specimens contain extractable prolactin. In a small series 
L-dopa was found to cause remissions in patients with advance breast 
carcinoma (Dickey and Minton^l972). It was also found that those patients 
whose tumours are prolactin-dependent will have more remissions after 
hypophysectomY than controls (Montague, 1977). Furthermore, the main 
evidence that prolactin might be of importance in human breast cancer 
comes from selection of data from animal models.
There is also evidence against prolactin having a role in human breast 
cancer. One of the earliest known features of epidemiology of human 
breast cancer is the inverse relationship of risk with parity (MacMahon 
et al., 1973). The fact that pregnancy in a decade or so after menarche is 
associated with reduced breast cancer risk implies that aetiologicalfactors 
are operating during that period of life. The extent of the reduction 
implies that this period is one of high risk of tumour initiation.
The hypothesis that lactation lowers breast cancer risk has existed 
for at least 50 years. Several studies indicated little or no difference in 
the lactation experience of breast cancer patients, and controls (MacMahon 
and Feinleib, 1960 ; Wynder et al., 1960; Levin et al., 1964). However, most 
of these studies were in countries with high breast cancer rates. The one 
study in a low risk area, Japan, reported a protective effect of lactation 
(Kamoi, 1960).
that
Bioassay using the pigeon crop method has suggestec^prolactin levels 
may be elevated in breast cancer patients,but Turkington etaL , (1971) using a 
different bioassay failed to confirm this (Berle and Voigt, 1972).
Premenopausal and postmenopausal patients have been found to have 
normal prolactin levels (Boyns et al., 1973). In another series, the prolactin 
level at diagnosis of breast cancer was normal (Wuttke et al., 1971).
It appears, therefore, that the controversy over the role of prolactin 
has not been completely resolved at the present time. All that can, 
therefore, be said^at this stage^that some human breast cancers may be 
prolactin dependent.
1.8.5.4 The Prolactin Lipid System
There is considerable literature from comparative physiology
suggesting an important role for prolactin and the regulation of fat
metabolism, but this has been obscured by the emphasis (exemplified by the
<>.r  name of the hormone) placed on the relationship between prolactin
and lactation. Studies concerning the liporegulatory role of prolactin have
been conducted principally by Meir (1977) in amphibians, birds, and lower
mammals. It is clear from this work that mobilization and deposition of
fat is regulated by diurnal (CNS-mediated) variations in serum prolactin
concentrations, and furthermore that these changes are temporarily
associated with changes in serum corticosteroid concentrations.
Insight into the mechanism by which prolactin regulates lipid
mobilization and deposition is provided by the work on^enzyme lipoprotein
lipase (zinder et al., 1974 ; Garrison and Scow, 1975). They found that the
activity of this enzyme in the rat was elevated during lactation and
specifically by prolactin. Since lipoprotein lipase activity represents the
major route by which triglyceride fatty acids are cleared from the
circulation, induction of this enzyme by prolactin substantiates a
liporegulatory function for this hormone.
Based on the foregoing consideration, Chan and Cohen (1974) designed
a series of experiments to assess the relationship between high fat intake,
prolactin secretion, and mammary carcinogenesis, ^ s  expected, drugs that
edantagonizedoestrogen action and blocks prolactin secretion, retarded tumour 
development. Only the antiprolactin drugs abolished the differential in 
tumour incidence characteristic of animals fed high and low fat diets. 
Though indirect, the results suggested that the fat effect was mediated by 
prolactin. It was also found that rats fed a high fat diet exhibited 
significantly higher serum prolactin levels than rats fed a low fat diet
It is also possible that dietary fat acts either at the ovary or at
higher centres controlling ovarian steroidogenesis, thereby stimulating
prolactin secretion and breast tumour development. This hypothesis is not
supported by evidence from experiments in which DMBA-treated rats were
ovariectomized one month after initiation and then placed on a high fat or
low fat diet (Chan et al., 1977). Ovariectomized animals fed a high fat diet
exhibited a marked increase in both tumour incidence and serum prolactin
u; 7 I'll
levels when compared animals fed a low fat diet. On the other hand, 
these results do not indicate that a role for oestrogens in the fat effect is 
completely eliminated. Oestrogens synthesized by peripheral 
aromatization of androgens could influence prolactin secretion patterns, 
and, thereby, indirectly influence mammary tumour development (Nature 
(London) Editorial, 1975).
In summary, studies in model systems support the proposition based 
on epidemiological considerations, that increased dietary fat intake is 
positively associated with breast cancer risk. It is suggested that prolactin 
mediates the fat effect by virtue of its dual capacity as a liporegulatory 
hormone and as a promoter of mammary tumour development.
Since experimental studies in rodents suggested a link between 
dietary fat intake, prolactin hypersecretion and breast cancer risk, Hill and 
Wynder (1976) conducted a series of dietary intervention experiments to 
determine whether a similar relationship existed in humans. In the first of 
three studies, volunteers were placed on a standard Western diet for 2 
months and then switched to a strict vegetarian diet for 2 months. After 
each dietary regimen, overnight prolactin patterns were measured. The 
data indicated that there was a marked increase in plasma prolactin 
concentrations during periods of peak secretion (during deep sleep) in
women on a high-fat standard Western diet compared low-fat vegetarian 
diet. In the second study involving healthy premenopausal women, morning 
plasma prolactin levels were measured every other day throughout the 
menstrual cycle after two months on a Western diet and 2 months on 
vegetarian diet (Hill et al., 1977a). It was found that the mean prolactin 
levels averaged over the entire menstrual cycle were greater after 2 
months on a Western diet than after 2 months on vegetarian diet.
To conclude, although evidence for the role of prolactin in human 
breast cancer is still largely indirect, there is a growing body of evidence 
to suggest that some prolactin secretion patterns are associated with 
increased risk for breast cancer.
It is reasonably certain that the blood lipid pattern changes after 
surgery as part of the postoperative response and that it may take some 
time to revert to a stable pattern. In addition, according to Barclay (1959) 
changes in pattern are associated with removal of the tumour, and thus 
patterns after operation may bear little  resemblance to what it was when 
the tumour was present.
\
It  seemed necessarily, that the changes occurring postoperatively 
in breast cancer patients were not peculiar to patients having this type of 
surgery. Similar investigations were therefore carried out in a group of 
patients having surgery for femoral fracture. The metabolic response to 
trauma is affected by a number of variables, which will be discussed later.
-36-
1 .9  METABOLIC RESPONSE TO TRAUMA
1 . 9 . 1  Introduction :
The nature and severity of an injury, whether arising by accident, 
necrotizing agent, radiation, or by elective surgery, condition the 
character of both the immediate and subsequent biochemical changes that 
occur not only locally^but also generally (Cuthbertson and Tilstone, 1969). 
Although these changes have been spasmodically studied for many years 
and as early as 1794 John Hunter had realized that "there is a circumstance 
concerning accidental injury which differs from disease, namely, that the 
injury done produces not only the disposition but the means of cure"; 
nevertheless, the nature of these changes and their interpretation still 
constitutes a fundamental and important area of biochemical research as 
accidents increase and surgeons become more venturesome (Cuthbertson 
and Tilstone, 1968).
It is now many years since Cuthbertson (1942) first put forward the 
idea of ’ebb' and 'flow' phases after injury. The former phase may last for 
24 to 72 hours, the latter is generally over in two weeks but in severe 
injuries may last up to eight weeks or longer. The ebb phase corresponds to 
a period in which there is initially loss of vitality which may be transitory 
or more manifest and there may be some degree of primary or "neurogenic" 
shock. For defense and in order to initiate repair of the damaged tissues, 
the injury is generally followed by an increase in metabolic reactions ("flow 
phase").
Cuthbertson (1932) demonstrated an increased output of nitrogen in 
the urine following lower limb fracture. He concluded that the nitrogen 
came from the body's protein, mainly from skeletal muscle, and thus 
accounted for the muscle wasting known to follow injury. This finding
initiated interest in the metabolic and nutritional sequence of injury and 
has led to considerable improvement in the management of injured 
patients. It has long been known that injury and operation induce a 
diabetic type of state (Hays and Brandt, 1952). Evans and Butterfield (1951) 
described the "pseudo diabetes" of burns, in which non-ketotic diabetic 
coma may occur in previously non-diabetic patients. Such patients lose 
their diabetes when they recover from the burn. It was postulated that 
there may be a relative or absolute lack of insulin in the injured state 
(Allison, 1974). Following injury there are changes in the secretion of 
hormones other than insulin which affect carbohydrate metabolism. Thus 
there is an increase in the secretion of corticosteroid, catecholamines, 
growth hormone, and glucagon (Allison, 1974). Adrenaline and glucagon 
cause glycogenolysis in liver and muscle, leading to hyperglycaemia and 
depletion of carbohydrate reserves. Protein breakdown for gluconeogenic 
purposes is stimulated by cortisol whereas insulin enhances the transport of 
amino acids into cells and their incorporation into protein. These hormonal 
actions are compatible with the metabolic changes seen after injury. 
Significant changes are taking place with regard to our concept of energy 
metabolism in the period following injury and in septic patients (Irving and 
Stoner, 1981). The resting metabolic expenditure after elective surgery is 
increased by about 10-15% during the first few days. Metabolic 
expenditure is reduced by an almost similar amount at this time due to the 
immobility of the postoperative state (Johnston, 1974). Nitrogen excretion 
is increased at this time, but the increased metabolism is not due to protein 
oxidation. Measurement of the respiratory quotient indicates that the 
main fuel in these patients is fat (Irving and Stoner, 1981). In severely 
injured patients, fat is utilized shortly after the accident and often well 
into the "flow" phase; this use of fat can continue for some time in the 
severely septic patient (Askanazi et al., 1980).
1.9.2 Factors modifying the response to injury
A number of factors influence the extent and duration of the 
metabolic changes in the post injury period. These factors include the age, 
sex, body build and nutritional status of the injured subject, along with the 
presence or absence of pain, immobilization, starvation, sepsis, blood loss, 
blood transfusion, anaesthesia, and high calorie intake (Richards, 1977). 
The metabolic response is much less in women than in men of comparable 
weight and the greatest responses are seen in young muscular males. 
Patients who are underweight at the time of injury lost little  nitrogen 
afterwards and it  is a relatively easy matter to maintain nutritionally 
depleted patients in positive nitrogen balance after major injury. A 
marked fall in serum beta-lipoproteins and cholesterol is associated with 
the experience of pain, regardless of the pathology underlying it (Keele and
Stern, 1973).
■fcVyj.  v
In search for the cause of injury response, many other factors have
been investigated ; of these anaesthesia (Moore, 1957) and blood transfusion
were found to play a minor role (Timoner et al., 1959), unlike haemorrhage
which caused significant increase in urinary nitrogen losses (Flear and
Clark, 1955). Patients who are under-transfused at the time of surgery lose
more nitrogen in the urine than those whose blood volume is maintained
through surgery (Johnston, 1974). The metabolic response to open heart
surgery carried out under carefully monitored conditions is surprisingly
small. Prolonged immobilization in healthy volunteers also increased
urinary nitrogen excretion, but to a minor degree (Cuthbertson, 1929), when
compared to the overall injury response. Some workers considered that
partial starvation, which is a common occurrence after severe injury, was
the major cause of the marked post injury negative nitrogen balance
(Abbott and Albertson, 1963 ; Dudley, 1968), but others found that
injury and starvation occuring simultaneously resulted in an additive 
catabolic effect (Wilkinson, 1966). It was also known that it was possible to 
virtually eliminate the negative nitrogen balance after injury by feeding 
injured subjects high caloric supplements along with adequate amounts of 
protein (Cuthbertson, 1936).
The main environmental factor is ambient temperature. After severe 
injury the temperature falls and the body, makes little attempt to correct it 
(Little and Stoner, 1981). Nursing patients with long bone fractures at an 
ambient temperature in the thermoneutral range (30°C), decreases urinary 
nitrogen losses and prevents the depression of albumin synthesis which 
otherwise accompanies these injuries (Cuthbertson, 1970). An increase in 
the ambient temperature by 30% reduces the evaporative heat loss and its 
associated calorie expenditure (Johnston, 1974). This sparing of calories is 
reflected in a reduced excretion of nitrogen in the urine. Significant 
saving of body protein can be demonstrated when burn patients are nursed 
at high temperature.
The metabolic response to injury can be modified by a number of 
factors and the objective of surgical care should be to control the response 
by careful attention to technique during surgery and the maintenance of 
vascular, nutritional and environmental homeostasis at all times.
TV
1.9.3 Lipids and Trauma :
Until recently, alterations of lipid metabolism that accompany major 
injury or infection have received little  attention. A detailed understanding 
of these changes is an important prerequisite for )'%' determination of the 
optimal nutritional support regimen for acutely ill patients. The plasma 
lipids have been studied to some extent in different experimental animals 
(Johnson and Wadstrom, 1956; Wadstrom, 1958), after trauma and different 
results have been obtained.
During starvation after operations, trauma, etc., the main source of 
energy is the body fat (Wretlind, 1976) (Figure 1.2).
The mobilization and utilisation of lipid after injury was summarised 
by Carlson (1970). He emphasized that in patients with major burns, there 
was a marked early rise in the concentration of free fatty acids in the 
plasma and that the increase appeared to be proportional to the size of the 
bum. At the same time plasma triglycerides were relatively unchanged 
from the normal values. Upon infusion of Intralipid, these burn patients 
showed only a slight increase in plasma triglycerides, and the free fatty  
acid level actually decreased. Lipolysis is increased postoperatively and 
after bums. The plasma content of free fatty acids is accordingly 
increased after trauma and burns (Wadstrom, 1959 ; Allison et al., 1968). 
Thhs increased lipolysis serves a metabolic purpose. Rodewald (1962) 
showed that the respiratory quotient was decreased postoperatively, 
indicating that the great need for energy was mainly covered by combustion 
of fat.
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Man et ah, (1946) found that,scholesterol, phospholipids and the free 
fatty acids of neutral fat decreased following operative trauma in man. It 
is of interest in this connection that during the course of myocardial 
infarction the serum cholesterol levels have been found to decrease 
(Watson et al., 1963 ; Cotton, 1970; Fyfe et al., 1971). McNamara and 
colleagues (1972) demonstrated a rise in serum levels of free fatty acids 
and trigylcerides in combat injuries in Vietnam, and the degree of elevation 
appeared to be related to the severity of trauma.
Lepisto (1976) reported a detailed study of blood lipid changes ip ; 43
patients who sustained fractures of the leg or pelvis. The serum
triglycerides increased over 4 days, while a mild decrease in cholesterol 
and phospholipid were noted in 8 of the patients who were diagnosed as 
having the fat embolism syndrome. Lipoprotein fractionation showed no 
significant differences from normal.
Friedman and co-workers (1958) reported increases in serum 
cholesterol levels and decreases in blood clotting times in men subjected to 
cyclic variation of occupational stress. Several authors have found that 
serum cholesterol levels are elevated in students during periodic mental 
stress associated with examination (Grundy and Griffin, 1959 : Wretlake et 
al., 1959). Grundy and Griffin (1959) obtained blood samples from medical 
students during the middle of the winter academic quarter and these were 
compared with samples obtained during final examinations at the end of 
this quarter, with respect to serum lipoprotein and total serum cholesterol 
levels. The findings of this study indicated that serum cholesterol levels 
and low density lipoprotein are increased during mental stress. It is 
suggested that this increase may be the factor that related stress to 
atherosclerosis and coronary artery disease.
Fat embolism follows trauma (usually to bones). There is a lucid 
interval of variable duration and then signs of respiratory and systemic fat 
embolism develop, together with changes in the mental state and level of 
consciousness ; a petechial rash also occurs on the head, neck and thorax. 
O'Driscoll and Powell (1967) reported a significant lipaemia in 79 patients 
who were followed for a period of six days after trauma, and corresponded 
at its peak to the onset of fat embolism. There were 27 patients with some 
degree of fat embolism, three of whom died. They suggested that tissue 
injury may initiate changes in the physiochemical state of blood, and that 
this alters the emulsion stability of the blood lipids.
1.10 The Present Study
The work reviewed in the previous section reveals that injury causes 
a chain of events which results in alteration in plasma lipids. Initial 
experiments in this investigation are therefore concerned with a basic 
study on plasma lipids in a group of elderly patients undergoing orthopaedic 
surgery. This basic study was aimed at providing information as to the
nature of lipid metabolism in surgical trauma.
the
The literature survey discloses that;.plasma lipid profile may have 
particular significance in patients with breast cancer. There have been 
suggestions that a high fat intake may predispose towards the development 
of this condition, and serum cholesterol and lipase concentrations have 
been reported to be higher in patients with breast cancer than in age 
matched controls (Basu and Williams, 1975). Considering all these factors, 
further investigations in patients undergoing treatment for breast cancer 
were designed to test the following hypotheses :
1. That lipids play a role in the aetiology of breast cancer.
2. That the surgical removal of the tumour affects plasma lipid and 
lipoprotein concentrations.
3. If  abnormalities in plasma lipid levels are associated with the presence 
of an early tumour, it seems worth investigating the possibility that they 
may be used as a part of a screening programme as an identifiable risk 
factor.
of
The lipo-regulatory influence of prolactin should be considered on^its 
basic functions (Meir, 1977). The question is whether prolactin increases 
circulating plasma lipids or vice versa. Another aspect of this study was to 
investigate the role of prolactin in human breast cancinogenesis. Thus, it 
seems to be of interest to determine the level of plasma prolactin in 
patients with benign and malignant breast tumours, and to correlate this 
with plasma lipid values.
CHAPTER TWO :
MATERIALS AND METHODS
CHAPTER TWO 
MATERIALS AND METHODS
2.1 The Breast Disease Study
2.1.1 Subjects
It  was decided to study patients with early breast cancer referred
from a breast screening programme as well as patients with benign breast
disease. In order to identify the postoperative changes which may result
from removal of a breast tumour, we have studied the effects of surgery on
blood lipids. For the study of postoperative effects, patients have acted as
their own controls. It was agreed to base the study at the Surrey Royal
County Hospital, Guildford, as the patients were admitted for surgery, and
re.3u.l0vV Lvj
at St. Luke's Hospital, Guildford, as an outpatients Breast Clinic was^held 
\  - there.
Women were referred to St. Luke's Hospital Breast Clinic by their 
General Practitioner or from the Jarvis Screening Centre for further 
investigations. This centre is carrying a screening programme of bi-annual 
clinical examination and mammography^ with clinical examination alone in 
the intervening years. Of the 24069 women agbd 45-64 registered with a 
practitioner in the South West Surrey Health District? 69% attended for 
breast cancer screening, with resultant cancer detection rate of 5.5/1000 
women screened and a cancer:benign biopsy rate of 1:1.77 (Thomas et al., 
1983).
Screening detected 94% of all cancers occuring within a year in the
rscreened group and 84% of all cancers occuring in the population whether
women attended for screening or not. This may be called the Screening
it
Programme efficiency or sensitivity, and is the important figure with 
respect to an eventual change in mortality. The women had usually noticed 
a lump in their breasts or a nipple discharge, and visited their own doctors,
who referred them to the Breast Clinic, if  further consultation was needed. 
At the Clinic the patients were examined by one of the doctors and a 
detailed history taken. Arrangements were made if  necessary, for 
mammography or other tests. From the investigations a decision on
ivv i
treatment was made, and arrangements/Tor hospitalization if  required.
I began attending one of the Breast Clinics held each week at the
Radiotherapy Department, St. Luke's Hospital, on a Thursday afternoon, to
find out when a patient was admitted for treatment, and learn about the
problems of diagnosis. Contact was then made with the staff of Eashing
and Elstead female surgical wards at the Surrey Royal County Hospital to
which women seen at the clinic were admitted for surgery.
A meeting with doctors was arranged, and the details of the research
study was discussed. A system for the collection of the blood samples and
general information about the patients was devised. Due to the nature of
the project, an investigation involving patients with breast cancer, it was
decided that I should obtain the information I required indirectly from
hospital notes and from doctors, rather than questioning the patients
directly. The study was explained to the patients in terms of a research
investigation into the level of fat in the blood of patients in hospital.
Arrangements were also made with the house officers who were to take the
blood samples. This also applied to the patients with benign breast disease.
\w  dy'A s.y •to w vih iw tijg .
ALL tVis cA\ywoh /> patients coming to any false conclusions from the
questions I asked, the cause of the their cancerT or in case of patients
indeed
with benign breast disease concerning the possibility that they mighfyhave 
cancer.
Patients who were to receive surgical treatment for either benign 
breast disease or carcinoma of the breast were included in the study. 
Blood samples from 51 subjects with benign breast disease and 48 patients 
with cancer were collected (Table 2.1). Nine postoperative blood samples 
were acquired from the Haslemere and Cranleigh Hospitals.
The patients were divided according to menopausal status by 
reference to their case histories (Table 2.1). Further details are given in 
the appendix ( page 156).
There were 27 premenopausal cancer patients with a mean age of 44 
+ 1 years and a mean body weight of 60 + 2 kg., and 21 postmenopausal 
cancer patients with a mean age of 59 + 2 years and a mean body weight of 
6 6 + 3  kg. The non-cancerous group was subdivided into a premenopausal 
subgroup of 24 patients with a mean age of 3 9 + 2  years and mean body 
weight of 58 + 1 kg., and a postmenopausal subgroup of 20 patients with a 
mean age of 61 + 2 years and a mean body weight of 62 + 2 kg. As one 
group, the mean age for the cancer patients was 51 + 2 years and the mean 
body weight was 63 + 2 kg, ^the mean age for non-cancerous patients 
was 4 8 + 2  years and the mean body weight was 59 + 2 kg.
The patients with benign breast disease were subdivided into:
fibroadenoma (18 patients with a mean age of 43 + 3 years and mean body
weight of 61 + 2 kgs); a benign subgroup with other histopathological
features including lipoma and duct ectasia etc., (26 patients with a mean
age of 53 + 3 years and a mean body weight of 59 + 2 kg); and patients with
duct papilloma (7 patients with a mean age of 54 + 4 years and a mean body
tog«.Uie.v u iitU  having
weight of 70 + 4 kg). The patients with fibroadenomas /> those --A other 
histopathological features^form the non-cancer group (44 patients with a 
mean age of 48 + 2 years and a mean body weight of 59 + 1 kg). The 
patients with breast cancer were also divided with reference to their 
histopathological features (Table 2.1).
TABLE 2.1: Description of cancer patients and non-cancer control patients 
(Further details shown in the Appendix (p 156)
Description All
Cancer patients : Total 
In situ duct carcinoma 
Squamous Adenocarcinoma 
Invasive duct carcinoma 
Invasive lobular carcinoma 
Schirrous carcinoma 
Well differentiated tubular 
carcinoma
Breast cancer histopathology 
not reported
Non-cancer patients : Total 
Duct papilloma 
Fibroadenoma 
Other benign disease
Premenopausal Postmenopausal
27 21
4 3
5 4
10 9
1 -
1 -
1
6 4
24 20
5 2
13 5
11 15
Patients
48
• 7
9
19
1
1
1
10
44
7
18
26
2.1.2 Sample Collection
Patients having surgery for breast cancer had blood samples taken 
preoperatively (a) and postoperatively at 48 hours (b), 7 days (c), and 28 
days after surgery (d). Most of the patients in the benign group were 
discharged within less than 48 hours after . operation, the first blood 
sample (a) was taken preoperatively, and the second (d) 28 days after the 
operation. The samples a,b and c, were obtained by venepuncture from 
subjects in the morning after an overnight fast. Sample (d) was taken in 
the afternoon at an outpatient clinic and patients were asked not to have 
milk or fat (eg., margarine or butter) before attending the clinic. Samples 
were drawn into lithium heparinized tubes and immediately chilled in ice. 
These samples were centrifuged within two hours of collection and the 
plasma stored at - 40°C until analysed. All the samples were stored under 
identical conditions, but the time of investigation varied, the maximum 
being 15 months.
2.1.3 Information
Wherever possible the following information was obtained from each 
of the patient's notes :
Age
Weight, height 
Presentation 
TNM classification 
Menopausal status 
Parity
Use of oral contraceptives : now/previous/never
ovaries removed/conserved
hysterectomy yes/no
serious illness, medical or surgical
history of drugs
histopathology
plan of treatment
This information could only be obtained from the hospital case notes, and 
was in some cases incomplete.
2.2 The Orthopaedic Surgery Study
2.2.1 Subjects
A total of 27 patients were studied (see Appendix for details page 
162). These were in two groups. The first group (14 females and 4 males) 
were undergoing emergency surgery for femoral neck fracture, with a 
mean age of 81 + 2 years. The second group (6 females and 3 males) with a 
mean age of 74 + 3 years, were undergoing elective total hip replacement.
2.2.2 Sample collection
The blood samples were all taken at 8 a.m. after an overnight fast. 
The samples which were in lithium heparinized tubes, were centrifuged 
within two hours of collection and the plasma stored at - 40°C until 
analysed. Blood samples were taken from the first group postoperatively.
The first samples (b) were taken 48 hours postoperatively ; the second
at and at
sample (c),^7 days ;/*the third (d), 14 days postoperatively. In the second
elective surgery group, the first sample (a) was taken preoperatively; the
at and
second (b) 48 hours postoperatively; the third (c),f7 days ;^the fourth (d), 14 
days postoperatively.
A previous study was done in the first group to assess nutritional 
status of these patients (Older et al., 1980). The elective surgery group was 
also investigated in a previous nutritional survey (Older et al., unpublished). 
Each sample was assayed for :
a. total lipids
b. total and HDL cholesterol
c. total triglycerides
Before starting work on measuring concentrations in the test samples the 
methods were practiced and tested for reproductibility using appropriate 
standards.
2.3 General Precautions taken in lipid analysis
The pioneering work of Bloor and Knudson (1917) marks the real 
beginning of the quantitative biochemistry of blood lipids. The measured 
values for circulating levels of lipids and lipoproteins are affected by a 
number of factors, many of which are related to laboratory methods and 
manipulations. Some of the factors that affect lipid and lipoprotein 
measurements are the following :
1. Posture
It has long been recognized that plasma volume increases, and the
concentration of n on-diffusible plasma components decreases, when a
standing subject assumes a recumbent position, due to redistribution of
water between vascular and extravascular compartments (Bachorik,1979).
These changes would probably not be thought of as causing errors in the
lipoprotein analysis, since they may occur physiologically; they can,
nonetheless, complicate interpretation of the measurements made,
in
in population surveys, andfblood sampling*conditions should be 
standardized to one position*if possible.
-52-
2. Venous occlusion :
Prolonged venous occlusion prior to venepuncture can cause 
appreciable increases in the apparent concentration of non-diffusible 
components. Serum cholesterol concentrations were found to increase an 
average of 10-15% after a 5 minute period of occlusion (Page and 
Moinuddin, 1962). From a practical standpoint, errors of this magnitude 
would not normally be encountered, since the tourniquet is usually removed 
within 30-60 seconds.
The precautions that should be observed in obtaining and handling 
blood specimens are :
1. All plasma lipid determinations should be carried out on fasting 
samples. Patients are instructed to take nothing by mouth other than 
water for 12-16 hours prior to sampling.
Since certain drugs might seriously influence lipid measurements by
. ivnporUht
the methods used, it  is to collect data about medication taken
by the patient. It should be ascertained whether female subjects are 
pregnant since blood lipid levels are affected by pregnancy.
2. It is to standardize posture. The sitting position seems to
be most commonly used (Manual of Laboratory Operation, LRC 
Programme, 1974).
3. Plasma is preferred to serum for lipid determinations because :
viUidU
1. EDTA chelates heavy metals, may promote auto-oxidation of 
lipids.
2. There is no need to allow blood to remain at room temperature for 
coagulation to occur.
3. It is difficult to recover chylomicrons from lipaemic sera, and
4. Heparin in solution is a convenient anticoagulant, having little  or 
no effect on blood lipids.
4. Blood samples are cooled on ice as soon as they are collected. Within
H
3 hours the tubes should be ce trifuge at 1500 g for 30 minutes.
5. Three basic precautions should be observed in the storage of all lipid 
samples :
1. They should be stored at as low temperature as possible, but in any 
event at least at - 20°C.
2. Oxygen should be excluded from the sample during storage, and 
during handling if  possible.
3. The sample should be stored in the dark.
If these precautions are taken, samples can be stored for long periods; 
samples can be stored in screw-cap vials when the caps have been 
thoroughly washed, cleaned and lined with Teflon or polythene seals. 
Hydrocarbon base oils and greases are to be avoided.
Finally^in storing lipid extracts and samples it is mandatory to use 
to
low temperatures and ^ exclude oxygen. Samples in solution and in the 
presence of antioxidants can be stored almost indefinitely^ if  proper
conditions are observed (Nelson, 1979).
Analytical Methods
2..4.1 Determination of Total Lipids
A colorimetric method was used for measuring the total lipids 
(Zollner and Kirsch>1962). The principle of the method is that lipids react 
with sulphuric and phosphoric acids and vanillin to form a pink coloured 
complex. The method involved using a diagnostic reagent, Cat. No. 
124303. The kit was obtained from Boehringer Mannheim Company. 
Reagents :
Contents Initial Concentrations
1. Standard total lipids
2. Colour reagents
Phosphoric acid 
Vanillin
3. Additional Reagent 
Sulphuric Acid, Cone., A.R.
1000 mg/100 ml
14 moL/l 
13 mmoL/l
Procedure :
Wavelength 
Spectrophotometer 
Cuvette
Reaction temperature 
Measurement Temperature 20-25°C 
Measure against blank.
530-360 nm 
530 nm
1 cm light path 
100°C
Pipette into dry test tubes :
blank standard
Solution I - 0.05 ml
Sample
Sulphuric acid - 2.0 ml
The tubes were mixed well, being plugged with cotton wool, and 
placed in a boiling water bath for 10 minutes. The tubes were then cooled 
in a water bath and the following amounts were pipetted into dry test 
tubes.
blank standard sample
from above solutions - 0.10 ml 0.10 ml
Sulphuric acid 0.10 ml
Solution 2 (colour reagent) 2.5 ml 2.5 ml 2.5 ml
The tubes were mixed thoroughly, the solution poured into cuvettes. 
The absorbance of sample and standard were read against the blank.
sample ^ 
standard
Calculation :
The concentration of total lipids in plasma =
1000 X samPtg- mg/lOOml = 10 X
standard
sample
0.05 ml 
2.0 ml
2.4.2 Determination of Plasma Cholesterol
The o-phthalaldehyde method was used (Zlatkis and Zak, 1969). 
Comparison of this method with the ferric chloride method gave identical 
results (Rudel and Morris, 1973).
However, the o-phthalaldehyde determination is three times more sensitive 
than the ferric chloride determination and it takes less time to complete 
and the colour developed is more stable.
Chemicals and reagents :
1. Potassium hydroxide 33% (w/v) 33g in 100 ml distilled water.
2. Cholesterol Standard.
Cholesterol was obtained from BDH Chemicals Ltd. It was made up 
to 10 mg/ml ethanol for use as stock standard. Cholesterol working 
standard :
0.5 ml, 1.0 ml, 2.0 ml, 3.0 ml, and 4.0 ml of the stock standard was diluted 
to 10 ml with absolute ethanol to 50, 100, 200, 300, and 400 mg/lOOml.
3. O-phthalaldehyde was purchased from Sigma Chemicals Company, a
acid |
working solution of 50 mg/lOOml in glacial acetic/twas prepared freshen the
day of use.
Procedure :
Using glass tubes, 20 X 100 mm with Teflon caps to fit, the following 
reagents were pipetted :
test standard blank
Plasma 0.10 ml -
Cholesterol standard - 0.10 ml
Absolute ethanol - - 0.10 ml
KOH 33% 0.30 ml 0.30 ml 0.30 ml
95% ethanol 3 ml 3 ml 3 ml
All tubes were stoppered and mixed thoroughly in a tube vibrator. 
Then the tubes were placed in a water bath at 60°C for 15 minutes. After 
the mixture had cooled, 10 ml of hexane was forcefully added to each tube 
to mix with the lower layer. 3 ml of distilled water was added to all tubes. 
The tubes were capped and shaken in a whirlmixer for one minute to ensure 
complete mixing. Appropriate aliquots (1 ml) of the hexane layer were 
pipetted into test tubes, and the solvent was evaporated under nitrogen. 2 
ml of the O-phthaladehyde reagent was added to each tube, and the 
solution was thoroughly mixed to dissolve all samples. About 10 minutes 
after the addition of the O-phthalaldehyde reagent, 1 ml of concentrated 
sulphuric acid was carefully added by allowing it to run down the inside of 
the tube. Then the contents were carefully mixed.
Absorbance was read on an SP500 colorimeter at 550 nm, between 10 
and 90 minutes after addition of the concentrated sulphuric acid. A typical 
standard curve is shown in Figure 2.1
2.4.3 Isolation of high density lipoproteins
The method was that described by Allen et al., (1979). The method is 
based on precipitation of lipoprotein other than HDL, followed by measure 
ment of cholesterol in the supernatant fluid using the O-phthalaldehyde 
reagent (Rudel and Morris, 1973).
Reagents :
PEG : polyethylene-giycoi, average relative molecular mass of 6000 
daltons (British Drug House) in distilled water 200 g/l .
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Procedure :
1. 0.2 ml plasma was added to 0.2 ml PEG - 6000 in a plastic centrifuge 
tube. This was mixed using a vortex mixer.
2. The reagents were allowed to precipitate for 1 hour at room temperatu 
re, and the tubes were centrifuged for 20 minutes at 2000 g-i.e., 3200 rpm 
using a Beckman J-6 Centrifuge.
3. The supernatant was aspirated with a Pasteur pipette for cholesterol 
analysis.
4. 0.10 ml of the supernatant was taken and cholesterol estimation 
undertaken using the O-phthalaldehyde method (Rudel and Morris, 1973).
2.4.4 Isolation of 3-lipoproteins
The test principle is that 3-lipoproteins are precipitated with calcium 
chloride/ heparin and their concentration is determined by compiexing the 
cholesterol fraction with sulphuric acid/acetic acid/acetic anhydride. The 
method involved uses a diagnostic reagent, Cat. No. 1224931. The kit was 
obtained from Boehringer Mannheim Company. The method was that of 
Watson (1960).
Reagents :
Contents Initial concentration of 
Solutions
1. Standard Cholesterol/ 
Galacial acetic acid
200 mg/lOOml
2. Heparin/Cad^ Heparin
Calcium chloride 
Sodium chloride
0.0123%
25 mmol#/l 
3.8 mmok/l
3. Colour Reagent Acetic Acid 
Acetic Anhydride
7 molf/1. 
6.5 moL/1
Sample Precipitation :
50 pi plasma was pipetted with 2ml solution 2 into a 10 ml centrifuge 
tube, mixing well. This was allowed to stand for 15 minutes, at 20-25°C  
and then centrifuged for 15 minutes at 3000 rpm. The supernatant was 
poured off carefully and discarded. The tubes were then allowed to stand 
inverted to drain on a filter paper for 45 minutes to remove any residual 
supernatant. The precipitate was used for cholesterol determination.
or on precipitate tube
Blank Standard Sample*
Distilled water 0.05ml
Solution I (standard) - 0.05ml
Solution 3 (colour
reagent) 2.5ml 2.5ml
*  This sample is prepared as referred to above.
The reagents were mixed and blank, standard and sample were 
allowed to stand in a water bath for 5 minutes at 20-25°C. 0.5ml sulphuric 
acid was added to all tubes. The tubes were quickly mixed and le ft in a 
water bath for 10 minutes. The solutions were poured into dry cuvettes and 
the absorbance of the sample and standard measured against the blank.
2.5ml
Procedure :
Wavelength 578nm (560-580)
Incubation 20 - 25°C
Pipette into dry test tubes (blank and standard) 
(containing the sample)^following amounts :
Calculation :
The concentration of total lipoproteins in the plasma =
570 X sample mg/lOOml
standard
The concentration of 8 -lipoprotein cholesterol in the plasma=
200 X samPle mg/lOOml
standard
2.4.5 Determination of Total Triglycerides 
Principle:
Heptane was used for the extraction of the triglycerides. These
are
procedures (Gottfried and Rosenberg, 1973) ^a modification of the Levy 
(1972) method in which nonane was used for extraction. The extracted
triglycerides were then determined colorimetrically according^the method
wire
of Van Handel (1961); hydrolysed to glycerol, which was oxidised with
periodate, and the resulting formaldehyde condensed with acetyl acetone,
wVtitW mere.
to form a yellow dehydrolutidine derivativermeasured colorimetrically. 
Reagents :
1. N-Heptane (Analar) was obtained from BDH Chemicals Ltd.
2. Isopropanol, reagent grade, was purchased from BDH Chemicals Ltd.
3. Sodium Metaperiodate, 6g/(., including 50ml of glacial acetic acid, were 
obtained from Sigma Chemical- Company.
4. Ammonium Acetate (2moL/| )
5. Acetyl Acetone Reagent : 1.5ml of acetyl acetone (BDH Chemicals 
UR/e.
Ltd).diluted to 200ml with ammonium acetate (2mol /I ) 
r
6. Triolein Stock Standard Solution • 300 mg/lOOml isopropanol. The 
Triolein was purchased from Sigma Chemical Company.
7. Triolein working standard : dilute 4ml, 2ml.and lml of stock standard to 
6ml isopropanol (equivalent to 200mg, lOOmg and 50mg/100ml).
Procedure :
Using stoppered glass tubes, 13X 100mm, the following reagents were 
pipetted :
Blank Standards Sample
Plasma
Water 0.5ml
Standards
Heptane 2ml
Isopropanol 3.5ml
Sulphuric Acid 1.0ml
To 0.4ml of the heptane (upper) layer from the extraction procedure, 
2ml of isopropanol, and one drop of potassium hydroxide (6.25mol /I ) was 
added. The tubes were mixed well, stoppered and incubated at 70°C for 10 
minutes. 0.2ml of sodium metaperiodate reagent and 1 ml of acetyl 
acetone reagent was added. The tubes were mixed well and stoppered and 
incubated at 70°C for 10 minutes. The mixture was cooled at room 
temperature for about 30 minutes and then the absorbance was read on an 
SP500 colorimeter at 425 nm.
The standard curve (Figure 2.2) was prepared by plotting the 
concentrations of standards vs absorbance. An experiment was carried out 
to demonstrate the effect of time on colour change in blank and standard 
after cooling (Figure 2.3). An experiment to show the effect of vortexing 
time on absorbance was carried out (Figure 2.4).
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2.4.6 Non-esterified Fatty Acids
A colorimetric method (Duncombe, 1964) was used for measuring
total free fatty acids. The test principle is that non-esterified fatty acids
are converted to cholorform-soluble copper salts, the copper in the organic 
.k-uvig
layer  ^ subsequently measured colorimetrically. The concentration of the 
non-esterified fatty acids is proportional to the absorbance of the copper 
containing chloroform. The method involved using a diagnostic reagent, 
Cat. No. 126055, from Boehringer Mannheim Company.
Reagents:
1. Solution I (Buffer-Cupric Nitrate)
Triethanolamine buffer 0.45 mol/l pH 7.8 
Cupric Nitrate 0.27 mol/l
2. Solution II
Diethyldithiocarbamate 9 mmol/1
3. Chloroform A.R.
4. Palmitic Acid A.R.
5. Fatty Acid Standard 0.5 meq/l
Palmitic%12.82mg) acid was dissolved in 100 ml of chloroform. The reagent 
is stable for 6 months when stored in the dark at 15-25°C.
Procedure :
Wavelength Hg 436 nm(420-450 nm)
Temperature 20 - 25°C 
The extraction of the copper salts should be carried out in ground-glass 
stoppered centrifuge tubes using a mechanical shaker. The stoppers must 
never be greased.
The following reagents were pipetted into 10 ml ground glass stoppered 
centrifuge tubes :
Blank Standard Sample
Chloroform 5.0ml 5.0ml 5.0ml
Standard 0.2ml
Plasma 0.2ml
Distilled water 0.2ml
Solution I 1.0ml 1.0ml 1.0ml
The tubes were shaken vigorously for 10 minutes using a mechanical shaker 
and then centrifuged for 5 minutes. The blue green aqueous layer (together 
with the protein layer) were carefully drawn off by means of a fine tipped 
pipette connected to a water-jet aspirator. Care was taken to remove the 
layers completely. 2.0ml chloroform and 0.2ml solution II were pipetted 
into all tubes. The tubes were mixed and after 10 minutes the absorbances 
of sample and standard were read against the blank. If  the concentration 
of non-esterified fatty acids exceeded 2 meq/l the assay was repeated 
with 0.1ml plasma and the results multiplied by 2.
Calculation :
The concentration of the non-esterified fatty acids in plasma (c) = 
c = 0.5 X A sample meq/l
A standard
2.4.7 Determination of Lipase
The method was that of Verduin (1973). The test principle is that
lipase catalyses the reaction :
Triolein + 2 H„0 lipase monoglyceride + oleic acid (2 moles). The  ^ ^
decrease in turbidity is measured in the UV-range. The method involved 
using a diagnostic reagent, Cat. No. 263346, which was purchased from 
Boehringer Mannhein Company.
0.30 mmoL/L 
26 mmol/l phj 9.2 
Sodium desoxycholate 19 mmoL/l
Calcium chloride 0.1 mmoL/L
Colipase 3mg/l
2. Standard
N.B. Lipase - see bottle label for activity in I.U./I .
Preparation of the reagent solution :
The contents of one bottle of lipase reagent was dissolved in 2.5 ml 
distilled water. Heat to 25°C before use. This reagent is stable for two 
weeks at +4°C, or five days at 15°C.
Preparation of standard solution :
1.0ml of distilled water was pipetted into the standard bottle and the 
contents dissolved by gentle swirling over a period of 30 minutes. The 
formation of foam was avoided. The standard is stable for 5 days at +4°C 
and 8 hours at +15°C.
Procedure :
Wavelength Hg 365 nm (340 nm or Hg 334 nm)
Temperature 25 - 30 °C  
Measure against air.
Reagents :
1. Lipase Reagent : 
Triolein 
Tris-buffer
Plasma (0.1ml) was pipetted into a reagent solution (25°C). The contents 
were mixed avoiding the formation of foam. The contents were then 
poured into a cuvette and read absorbance (A^Vour minutes after the 
sample was added, absorbance (A 2 ) was read after another 5 minutes.
A sample = Aj - A2
The absorbance of the standard was determined once (by duplicate assay)
for each pack. The A  standard was required for calculation.
Calculation :
Lipase activity =
I.U./L (25°C) =A sample X activity of standards (I.U ./|^
^standard
2.4.8 Prolactin Assay
Human prolactin was determined by a heterologous double antibody 
radioimmunoassay in the Radioimmunoassay Unit at St. Luke’s Hospital, 
Guildford. Internal quality control specimens (low, medium and high) were 
included at intervals in each assay, as well as several carry-over specimens 
from previous assays. The results were expressed as mU/l and the upper 
limit of normal range was taken as 360 mU/[ (Teale, 1983).
Prolactin Assay
Reagents
Buffer
Anti-PRL
Label
Phosphate buffered saline, 0.01M, pH 7.4 containing 1% 
B.S.A. Stock solution of A (K ^ P O  68g/l V and B 
(Na2 HPO^ - 2 ^ 0 ;  89g/l  ^ both containing 0.1% thiomersal 
were stored at 4^C. For use, 4 ml of A and 16 ml B were 
mixed, diluted to 1 litre and 9g NaCl added. This solution 
was stored at 4°C. Assay diluent was prepared by the 
addition of B.S.A. to buffer to a final concentration of 1%.
Serum (Guildhay) Rabbit-anti-PRL serum (batch G/R/51-
VABC) was diluted to 1 : 400 with phosphate buffered 
saline containing 0.5% B.S.A. and freeze-dried in 1 ml 
aliquots. For use, each aliquot was diluted to 120 ml in 
assay diluent. (Initial antiserum dilution is therefore 1 : 
48000; final dilution 1 : 96000). Normal rabbit carrier 
serum was added to an initial dilution of 1 : 600.
Prolactin for labelling was supplied by North East Thames 
RIA Unit, St. Bartholomew's Hospital. Iodination was 
carried out using lactoperoxidase, according to the 
attached method. Aliquots (100pl) of label were stored 
frozen and used at a dilution calculated from the data of 
each iodination, such that 100 pi of label, when diluted, 
contained approximately IQOpg PRL and provided 
approximately 10,000 counts.
Second anti-serum (Guildhay) Donkey anti-rabbit lgG precipitating 
serum was used. It was used at an initial dilution of 1 : 20 
(final dilution 1 : 160). Each vial of freeze-dried serum 
was reconstituted with 1 ml distilled water and diluted for 
use in assay diluent.
Standards Ampoules of a reference preparation (75/504) of human
prolactin were obtained from the Department of 
Biochemical Endocrinology, Chelsea Hospital for Women, 
Dovehouse Street, London SW3 6LT.
Each ampoule contains 2,500 pU prolactin.
For use, to each tube was added 1 ml assay diluent to 
produce the top assay standard of 2,500 mU/[ • Standards 
were double diluted in transfusion plasma to produce 
standards of 1, 250, 625, 312, 156, 78, 39 m U/l •
Standard, Control and Test Sera Serum or plasma may be used. Blood 
bank transfusion plasma (preferably from a male donor) 
was used for dilution of the standards. Each batch of 
plasma should be checked to ensure it contained a low 
level of PRL (<50 m U /l •)
us«.ye.
Method Incubations » . carried out in polystyrene LP3 tubes. A
series of total, zero and standard tubes should be run 
before and after the test samples. Control specimens 
should be included at 10 sample intervals.
PROTOCOL
Additions (pi) Total Zero Standard Control Test
tubes tubes tubes tubes tubes
Transfusion Plasma - 100 - -
Standard Plasma - - 100
Control Plasma - - - 100
Test Plasma - - - - 100
PRL A/S - 300 300 300 300
Label 100 100 100 100 100
Second A/S - 100 100 100 100
Day 1 (Monday or Friday)
The standards were prepared, specimens and controls thawed and sufficient 
antiserum solution made up. To make up sufficient antiserum solution (see 
table below ).
No. of tubes 200 400 600
Diluent (ml) 60 120 180
PRL antiserum (ml) 0.3 1.0 1.5
Normal Rabbit serum (pi) 100 200 300
100 aliquots of serum/plasma were dispensed and 300pl of antiserum 
reagent added. Sufficient label solution was made up (see the following 
table).
No. of tubes 200 400 600
40 60
200 300
these were vortex mixed
Day 4 (Thursday or Monday)
Sufficient second antiserum reagent was made up (See table below).
No. of tubes 200 400 600
Diluent (ml) 20 40 60
Second A/S (ml) 1 2 3
100 ]il of second antiserum reagent was added to all tubes (except the 
total). These were vortex mixed and incubated at 4°C for 24 hours.
Day 3 (Friday or Tuesday)
All tubes (except the totals) were centrifuged at 2300rpm at 4°C for 30 
minutes. The supernatants were aspirated*ensuring that the tubes were 
kept cold during the period between centrifugation and aspiration. Any 
increase in tube content temperature may result in pellet disturbance.
All tubes were counted for a sufficient length of time to record at least
5,000 counts in the zero tubes. Both series of total, zero and standard 
tubes were counted before the sample tubes and a punched tape generated 
for use with the Wang computer programme. Alternatively, counts were 
plotted against standard concentrations and the controls and tests were
Diluent (ml) 20
Label Stock (yl) 100
100 y l of label solution was added to all tubes, and
and incubated at 4°C for 72 hours.
2.4.9 Total Phospholipid Determination :
The method is a modification of the original method of Fiske and 
Subba Row (1925). Many of the difficulties encountered in the original 
method were corrected through the use of vanadium pentoxide, a catalyst 
used in sample digestion and through other minor modifications (Naito, 
1975). The greatly improved speed, simplicity, accuracy, and precision of 
the method now makes the modified Fiske and Subba Row method ideal for 
research use.
Reagents:
1. Digestion mixture :
25mg Vanadium pentoxide (BDH Chemicals) were dissolved in 100ml 
concentrated perchloric acid (BDH Chemicals). Gentle heat was necessary 
to dissolve the vanadium pentoxide completely. This was heated on a hot 
plate and stirred magnetically for 8 hours. The reagent was stored in a 
brown bottle. The reagent is stable for one to two months.
2. Ammonium Molybdate (25g/l) :
2.5g Ammonium molybdate was dissolved in distilled water and 0.1 
ml sulphuric acid (conc.). This was diluted to 100ml. The shelf life of the 
reagent is one to two weeks. The reagent was discarded if a precipitate 
developed.
3. l-Amino-2-naphthol-4-sulphonic acid :
1.587g of Fiske and Subba Row Reducer (a mixture of l-amino-2- 
naphthol-4-sulphonic acid, sodium sulphite and sodium bisulphite), (Sigma 
Chemical Company), was weighed out. This was diluted to 100ml with 
distilled water. Care was necessary to completely dissolve the solution 
before use. The reagent is stable for about two weeks. When the solution 
became dark yellow, the reagent was discarded.
4. Trichloroacetic acid : 100g/l
The trichloroacetic acid was diluted with 1 litre of distilled water. 
This solution was stored away from bright light.
5.Phosphorus Stock Standard :
439.38mg potassium dihydrogen orthophosphate (BDH Chemical Co) 
was dissolved in 100ml of 2.3 mol of sulphuric acid.
6. Phosphorus Working Standards :
1 ml stock standard was diluted to 50 ml, 100 ml, and 200 ml with 
distilled water (equivalent to 20 mg, 10 mg, and 5 m g /l).
Procedures :
1. Digestion procedure :
Into 15 X 125mm glass tubes 0.1 ml plasma was pipetted. 3 ml 
trichloroacetic acid (100g/l) solution was added, and the contents were 
carefully mixed without allowing the precipitate to adhere to the wall of 
the tube above the solution. The tubes were allowed to stand for 10 
minutes at room temperature, and then the samples were centrifuged for 15 
minutes at 2000g (3000 rpm). The supernatant was carefully discarded and 
the precipitate was washed with 5 ml water, by resuspending it and then 
recentrifuging carefully. The supernatant fluid was discarded. It was 
important that every drop of supernatant was removed before adding the 
digestion mixture. To each tube 0.5 ml digestion mixture was added, and 
heated for about 15 minutes at 160°C on a heating mantle. Following 
digestion, the digestion mixture was allowed to mix with the contents of 
the walls of the tube by placing the tube in a horizontal plane and rolling 
the tube to allow the digestion mixture to wash the side of the tube. If  the 
mixture became light orange, digestion was incomplete. Digestion was 
carried out for a further 5 minutes. The digestion mixture should be clear 
and colourless for complete digestion. The mixture was allowed to cool to 
room temperature and 4 ml of distilled water was added.
2. Analysis :
After the digestion step was set up, the blank and standards were 
readjusted as follows :
Blank Standards
Digestion mixture 0.5ml 0.5ml
Working standards 
Water
lml
4ml 3ml
To all tubes, 1.0ml ammonium molybdate solution was added and the 
tubes mixed. 1.0ml l-amino-2-naphthol-4-sulphonic acid reagent, was 
added, mixed, placed in boiling water for 10 minutes. The tubes were 
cooled at room temperature and read at 660 nm. The spectrophotometer 
(SP 500) was zeroed with reagent blank.
3. Calculation :
The standard curve was drawn from lipid phosphorus (Figure 2.5). 
Because of the dilution factor, the figure was multiplied by a factor of 10 
to give mg/L from the graph (Figure 2.5) : therefore lipid P= mg/L (from 
graph X10). Total phospholipid mg/i = lipid P X 25 mg/1 ,* therefore 
phospholipid concentration = mq/1 = mg/lOOml.
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CHAPTER THREE 
Plasma Lipids in Patients with Breast Cancer
3.1 Introduction
Disturbances of lipid metabolism are a common feature of cancer 
patients (Begg, 1938). Proper evaluation of these disturbances is of major 
importance for elucidation of their origin, for appraisal of their effects on 
the course of the tumour process, and finally for making decisions as to the 
advisability and type of corrective measuresto be taken.
The lipids to which attention has been directed by investigators in 
cancer are phospholipids, cholesterol, lipoproteins, and fatty acids. The 
contention that cholesterol and common triglycerides such as cottonseed 
oil become carcinogenic upon heating to about 300°C has been for many 
years a controversial subject. Many aspects of the problem are covered in 
a review by Peacock (1946).
a
The presence of hyperlipidemic serum in patients with cancer has 
been noted for more than half a century (Mattick and Buchwald, 1929), but 
it  has been investigated only sporadically, and surprisingly few clinically 
orientated studies of plasma lipids in cancer patients We been carried out in 
the last decade, «i-n-is during the current era of detailed lipoprotein 
fractionation and analysis.
The importance of studying lipid metabolism in tumour patients 
follows from the role of cholesterol in cell proliferation (Chen et al., 1977)  ^
on the inhibitor effects of disturbances of carbohydrate-lipid metabolism
on the immune system (Dilman, 1977),on the immunosuppressive effects of
i^ cV\ <x$
some particular lipids, polyunsaturated fatty acids (Meade and Mertin, 
1978) on the possibility of influencing tumour growth by changes in lipid 
metabolism (Littman et al., 1966).
The incidence of breast cancer is higher in developed than in 
developing countries (LilienTeld, 1963), and within a country is generally 
higher in people of the higher socio-economic classes. That these 
differences are environmental rather than genetic, is suggested for 
example, by the fact that Japanese living in Hawaii have an incidence of 
breast cancer higher than that of Japanese living in Japan (Hill et al., 
1971a). In a review on nutrition and breast cancer, Dickerson (1979)has 
presented evidence which suggests that a high fat intake may be one of the 
factors in the aetiology of breast cancer. Earlier workers also found that 
animals fed fat-rich diets had an increased incidence of spontaneous breast 
tumours (Basu et al., 1973).
The present study was limited to patients with early breast cancer, 
most of whom had been identified in a screening programme (Thomas et 
al., 1983). Controls were patients with non-cancerous breast disease. 
Despite the close association between dietary fat and the incidence of 
breast cancer, biochemical investigation of the lipid status in breast cancer 
patients has been lacking. The present study was, therefore, designed 
principally to examine plasma lipids in patients with particular emphasis on 
the possible association of diet and breast cancer.
3.2 Results
3.2.1 Plasma lipids in cancer and non-cancer patients
Because some patients had already reached the menopause when they
as in
presented with breast disease*where others had not, both cancer and non­
cancer patients were divided into two groups of pre- and postmenopausal 
patients respectively. Since the age of onset of the menopause varies in 
different individuals, the separation into two groups was done by reference 
to their case histories rather than by reference to age. The average ages 
for the pre- and postmenopausal cancer patients were 44 and 39 years 
respectively^ and did not differ significantly from those of the 
corresponding group of non-cancer patients, 39 and 61 years respectively 
(Table 3.1). For the purpose of the comparisons in Table 3.1 no rt-f erenm 
was made to the type of cancer or the nature of the non-cancer disease. 
The duct papilloma patients were omitted from the data in Table 3.1. The 
data of these patients are considered separately (Tables 3.3 and 3.4).
The concentration of plasma total lipids in postmenopausal cancer 
patients was significantly higher ( P<0.001) than in premenopausal cancer 
patients (Tables 3.1 and 3.2). When considering the concentrations in the 
pre- and postmenopausal non-cancerous patients, there was a higher value 
in the post menopausal patients^but the difference was not statistically 
significant. Comparison of the plasma total lipid concentrations of 
postmenopausal cancer and non-cancer showed that the values were 
significantly higher in the cancer patients ( P<0.001). In the premenopausal 
patients also^the values for plasma total lipids were significantly higher in 
the cancer patients ( P<0 . 0 1 ) (Tables 3.1, 3.2).
Comparison of plasma total phospholipids, cholesterol, triglycerides 
and FFA concentrations of post-menopausal cancer and non-cancer 
patients showed that all the values were significantly higher in the cancer 
patients (PO.OOl). Further comparison in Tables 3.1 and 3.2 between the 
plasma total phospholipids, cholesterol, triglycerides and FFA 
concentrations in premenopausal cancer and non-cancer patients showed 
that these values too were significantly higher in the cancer patients.
With the exception of HDL-cholesterol, the mean concentration of 
total 3 -lipoproteins, 3 -lipoprotein-cholesterol and free fatty acids, were 
all higher in postmenopausal cancer and non-cancer than in those of 
premenopausal patients (Tables 3.1 and 3.2). The concentration of HDL- 
cholesterol was lower in the postmenopausal cancer patients and this 
combined with a higher level of cholesterol resulted in a lower HDL- 
cholesterol/total cholesterol ratio. Values for plasma lipase were similar 
in all groups of patients.
3.2.2 Plasma lipids in non-cancerous breast disease
The duct papilloma patients had mean values for total lipids, 
triglycerides, total cholesterol and free fatty acids which were 
significantly higher than in the fibroadenoma patients (Table 3.3). 
However, the HDL-cholesterol 3-lipoproteins and their cholesterol did not 
differ. Further comparison of plasma lipid values in duct papilloma 
patients with those with other benign disease showed that the levels of 
total lipids,^phospholipids and total cholesterol were significantly higher in 
the duct papilloma patients (Table 3.3). The other lipid profiles were not 
significantly different.
The cancer, non-cancer and duct papilloma patients were matched by 
age as in Table 3.4. When considering the plasma lipid concentration in 
cancer and duct papilloma patients significantly higher values were found 
for total phospholipids, triglycerides and FFA in the cancer patients (Table 
3.4). Further comparison in Table 3.4 between plasma lipid concentrations 
in duct papilloma and non-cancer subgroups showed that total lipids, total 
cholesterol,^3 -lipoproteins and its cholesterol were significantly higher in 
the duct papilloma patients.
ical
Regardless of the histopatholog  ^and type of breast carcinoma, the
plasma total lipid concentration was higher in the post menopausal patients
%
than those in the patients of reproductive age (Table 3.5).
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Table 3.2 :p Values between premenopausal and postmenopausal breast disease
pre vs. post­
menopausal 
cancerous
pre vs. post­
menopausal 
non-cancerous
pre­
menopausal 
cancerous 
vs. non- 
cancerous
post 
menopausal 
cancerous 
vs. non- 
cancerous
Age <0.01
Body Weight <0.03
Total Lipids <0.001
Total Phospho­
lipids <0 . 0 0 1
Total Trigly­
cerides <0 . 0 0 1
Total cholesterol <0.001
HDL- cholesterol <0.001
HDL-cholesterol
Total Cholesterol <0.001
3 -Lipoproteins <0.001
3 -Lipoprotein-
cholesterol <0 . 0 0 1
Free Fatty Aicids <0 . 0 0 1
Lipase NS
<0.001
<0.02
NS
<0.05
NS
NS
<0.05
NS
NS
NS
<0.001
NS
<0.05
NS
<0.01
<0.05
<0.001
<0.01
<0.001
<0.01
<0.001
<0.001
<0.001
NS
NS
NS
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
NS
Table 3.3 : Plasma I ipids in;,non-cancerous breast disease 
(Number of patients shown in parenthesis)
Values are mean + SEM
Fibroadenoma
(18)
Duct 
papilloma (7)
Benign 
cithers (26)
Age (years) 43* + 3 5 4 + 4 53+3
Body weight (kg) 61** + 2 7 0 + 4 5 9 * *  +2
Total ! ipids (mg/lOOml) 8 8 9 * * * + 4 0 1095 +102 8 5 3 * * * *  +
Total phospholipids 
(mg/1 0 0 ml) 295 +18 268 +17 295**  + 3
Total triglycerides 
(mg/ 1 0 0  ml) 136*+  5 151 + 6 147 + 16
Total cholesterol
(mg/lt>oml) 2 2 7 * * +  9 268 +4 2 2 2 * * * *  +
HDL- cholesterol .. 
Total cholesterol rauo 3 3 * * +  2 25 +3 3 1 * * *  + 1
Beta-lipoproteins 
(mg/lOOml) 467 +22 454 + 40 455 +18
Beta lipoproteins- 
cholesterol (mg/lOOml) 164+8 192 +14 161 + 6
FFA (meq/l ) 0 .6 7 * * +  0.005 0.70 +0.077 0.71 +.080
Lipase I.U./I 276 +3 276 +3 275 +3
HDL-cholesterol 6 9 + 3 6 4 + 4 6 6 + 2
Values significantly different from duct papilloma are shown : 
*  when p< 0.03 ;
* *  when p< 0 . 0 1  ;
* * *  when p< 0 . 0 2  ;
* * * *  when P< 0.001.
pcdUvvt's
Table 3.4 : Plasma I ipids infrduct papilloma matched by age versus cancer
and non-cancerous breast disease.
Age (years)
Body weight (kg)
Total Lipids (mg/lOOml)
Total Phospholipids 
(mg/lOOml)
Triglycerides
(mg/lOOml)
Total holesterol 
(mg/lOOml)
HDL-Cholesterol 
(mg/lOOml)
HDL-C/T otalC holesterol 
ratio
Total 8 -lipoproteins 
mg/1 0 0 ml)
8  -li po pro t ei ns-Gh ol est er ol 
(mg/1 0 0 ml)
(Number of patients shown in parenthesis) 
Values are mean + SEM
Breast 
Cancer (7)
5 4 + 4  
6 0 * *  +3  
1210 +139
FFA meq/l
Lipase I.U./I
278 + 25
6 0 + 4
2 2 + 3
566 + 58
185 + 21
! .17* * * *  +0.103
274 + 3
Duct Non-
Papilloma (7) Cancer (7)
5 4 + 4  
7 0 + 4  
1095 +102
368** * *+41  268 +17
178* * * * + 5  151+16
268 + 26
6 4 + 4
2 5 + 3
546 + 41
192 + 14
52 +3 
5 7 * * + 4  
762**  +47
278 +15
151+16
2 0 6 * * +  1 1
6 8 + 5
3 2 * +  2 
4 4 4 * * *  +36  
1 5 6 * * *  + 13
0.66 + 0.045 0.69 + 0.27
270 + 4 274 + 30
Values significantly different from duct papilloma are shown : 
*  when ' p<0.05 ;
* *  when P< 0.01;
* * *  when p< 0 . 0 2 ;
* * * *  when P< 0.001.
Table 3.5: Total I ipids (mg/lOOml) in patients with different kinds of breast tumours
Values are mean + 5EM
(Number of patients shown in parenthesis)
Pre-menopausal Postmenopausal All
Patients Patients Patients
In situ duct 920 -  28 1295 -1 1 6  1080 ±  89
carcinoma (4) (3) (7)
Squamous 990 -  45 1717 -  289 1313 - 1 7 5
adenocarcinoma (5) (4) (9)
Invasive duct 10691 82 1364 -1 6 8  1204 -  95
carcinoma (10) (9) (19)
Breast carcinoma 1220 — 207 1268 —189 1239 —139
Histopathology not reported (6 ) (4) (10)
3.3 Discussion
The high plasma lipid concentration observed in breast cancer
patients when compared with patients of similar age with other breast
diseases could result from a higher intake of dietary fat. If  this were so,
the data presented would provide some support for the epidemiological
studies suggesting a correlation between dietary fat and breast cancer.
Four separate lines of evidence support the importance of dietary
fatstC^The first derives from animal experimental studies, which have
demonstrated that both in the presence and absence of mammary
carcinogens the feeding of high-fat diets substantially increases the
incidence of mammary cancer (Carrol, 1973).
/  *
(11) The second line of evidence comes from population correlation 
studies which show a strong correlation between breast cancer incidence or
mortality and total dietary fat intake. Fat intake in different countries
sUbWj ' of-
, a positive correlation with incidence G r = + 0.79) (Armstrong and Doll,
4 v"oVY'
1975) and mortality ( r■= + 0.935)(Carrol and Khor, 1975) breast cancer.
There is* however, an exception to these correlations. The Greeks 
*  vlfc
have less than a quarter of the breast cancer incidence when compared >
the Israeli \ s despite having the same total dietary fat intake. Hirayama
(1978) has found a strong correlation between dietary fat intake and, breast
cancer age-adjusted mortality in 12 districts in Japan, a similar correlation
being observed with dietary pork intake,but not with any other nutritional
element.
(t»C) Another line of evidence derives from data demonstrating the
importance of height and weight as risk factors for breast cancer. Tall
t h e
women in Greece (Valaoras et al., 1969) and ^Netherlands (de Waard and
Baanders-van Halewijn, 1974) were found to have a greater risk of breast
cancer than women of average height. Lin et al., (1971) showed that in
Taiwan, women weighing more than 55 kg had a breast cancer risk twice
that of those weighing less than 45 kg. The risk was stronger among
women over 50 years, de Waard (1969) was first to suggest an association
between overnutrition or obesity and breast cancer. He found an increased
frequency of adrenal-related disease, such as obesity, diabetes, and
hypertension in postmenopausal cases of breast cancer and postulated that
the disease in older women is related to adrenal oestrogens, whereas in
younger women, it is ovary related. His hypothesis was based on the 
the ,
finding that after^menopause, adipose tissue instead of ovaries or adrenals 
produce oestrogens.
( \ ^  The final line of evidence comes from case control studies in which 
an attempt was made to directly assess*the dietary intake of fat in cases 
and neighbourhood controls. In such a study Miller et al., (1978) found that
the mean nutrient intake^as estimated by dietary history^ was greater for
for
the cases as a group than^the controls ^ though the differences were not 
statistically significant. A pilot study was carried out by Cutler (1980) at 
the Jarvis Screening Centre, Guildford. A daily fat score derived from a 
dietary history was used to estimate total fat intake of all subjects. The 
mean values of patients and controls were similar and with-out significant 
difference. The limited size of the population prevented any firm  
conclusions being drawn for the^association between total fat intake and
breast cancer. Recently Lubin et al., (1981)jby computing relative risks of
a ly
breast cancer in^case control study?found significant^increasing trends with
more frequent consumption of beef, pork, and sweet desserts.
In the present study the weight of eac(^  subjects was recorded. Body 
weight was significantly higher in postmenopausal than in premenopausal 
patients. This suggests that if we are to attempt to reduce weight and 
reduce the risk of hyperlipidaemia and of cancer, such an approach might 
have to be restricted to women from the time of menopause. However, the
present results may possibly increase our current understanding of breast
also
cancer, confirming the importance of environmental factors; it^.points to
the probability that nutritional factors are relevant, particularly the
consumption of total fat and possibly exess weight in postmenopausal
VKjifWowt cckY{iQ.\r
women. Furthermore^ \ . x  postmenopausal women^could be
followed to see whether they develop :w\odi^wav\c»j lecH  ,
Questions concerning lipid metabolism cannot be discussed without 
taking into consideration the fact that serum lipid levels are influenced by 
fat intake. The advice to eat less fat is given because of links between 
consumption of a diet in which fat supplied a large proportion of energy 
and the incidence of obesity, coronary heart disease (CHD) and certain 
cancers (Fallows, 1983). Breast cancer may also be linked with a high fat 
diet. it is more common in Western countries where diet is relatively high 
in fat (Wynder et al., 1960). Carrol et al., (1968) plotted per capita calorie 
and fat intakes against age-adjusted death rates from breast cancer for 24 
countries, and found significant positive correlations for both dietary 
factors.
Regardless of menopausal status plasma total lipids were 
significantly higher in cancer^than those with breast
disease. Moreover^ the plasma total phospholipid concentrations in breast 
cancer patients were higher than in those with non-cancerous breast 
disease,and this is in agreement with previous observations in patients with
“ 9 r
advanced breast disease (Basu and Williams, 1975). Phospholipids and
cholesterol are the major components of cell membranes- Tumours require
enough lipid so that membrane synthesis can proceed at sufficient rate to
permit rapid growth (Spector and Brenneman, 1973). The derangement in
ir e U W o v i
phospholipid metabolism is associated with a possible secondary/* to the 
presence of breast cancer.
Plo^ wia
Interest in the value of ^ cholesterol levels \v\ breast cancer studies
has arisen for several reasons : to identify for preventive purposes groups
at high risk of cancer, to search for clues to cancer causation and
pathology, and to evaluate the that of blood lipid
\v\1Ws
levels could decrease the risk of the disease; total cholesterol
concentration in the breast cancer patients were higher than in those with 
benign breast disease (Basu and Williams, 1975 ; Wallace et al., 1982).
Dyer et al., (1981) reported a significantly higher mean cholesterol level 
among women dying of breast cancer than among women alive 5 years 
after lipid screening. The hypercholesterolaemia observed in our patients 
was similar to the observation by Dilman et al.,(1981) who found that total 
cholesterol was significantly higher in breast cancer patients than in 
fibroadenoma tosis. This hypercholesterolaemia could be related to an
abnormal level of LCAT (lecithin cholesterolacyl transferase).
In an ; editorial in the Lancet (1980)  ^it  was stated that a low . 
cholesterol level predisposes to cancer."^/pjosqbt £ j
ivMide.vxc-e. -cwiA bUod t?L- Vncuj be^he data of
Hiatt et al.,(1982) showed that no direct relation exists between the results 
of a single serum cholesterol determination and the subsequent 
development of breast cancer in women. In the former case the lowered 
cholesterol level could be a result of systemic effects of the tumour which 
does not manifest itself clinically. In the latter case the negative
association could be the result of the choice of control, time of diagnosis 
of breast cancer,6 : — -.v
„ Williams and coworkers (1981) found an 
insignificant negative correlation between serum cholesterol and breast
cancer in the Framingham Study. Further work that examines time of
o-f c&ncey
diagnosis^in relation to serum cholesterol is needed. In our
study the high cholesterol level could be a time risk factor for tumour 
development.
Relatively high blood triglycerides were found in patients with
cancer compared with healthy controls of the same age (Dilman et al.,
1981). The present study has documented a similar lipid abnormality in 48
patients with breast cancer, and demonstrates that this specific pattern of
lipid alteration, L is markedly common in
such patients,differing only in degree.
The most probable mechanism underlying this observed
hypertriglyceridaemia is an abnormality of either (LCAT) or lipoprotein
lipase. Confirmation of this hypothesis needs further direct research.
In the present study cancer patients had the greatest concentration
of free fatty acids. Feldman and Carter (1971) carried out a comprehensive
survey of plasma lipids in women with metastatic carcinoma of the breast
v«\\o
who were postmenopausal or A had undergone  ^radiation or surgical 
castration. They showed that the concentrations of free fatty acids were 
significantly higher than in a control group of healthy postmenopausal 
women. The mean value for plasma non esterified fatty acids for the 
cancer patients had also been shown to be significantly higher than that of 
patients with chronic disease other than cancer (Mueller and Watkin, 1961). 
Tumour-bearing animals develop elevated plasma fatty acids 
simultaneously with the loss of carcass lipids (Frederick and Begg, 1958).
Questions concerning lipid metabolism cannot be discussed without 
taking into consideration the fact that the blood lipids are components of 
circulating lipoproteins. HDL-cholesterol was significantly lower in breast 
cancer patients than in those with benign breast disease. Among lipid and 
lipoprotein alterations noted in patients with malignancy, high density 
lipoproteins appeared to be the most sensitive to tumour burden. Recently, 
marked variations from normal have been observed in some lipoprotein 
fractions of the blood of human cancer patients. The blood concentration 
of high density lipoprotein cholesterol in patients with breast, lung, and 
stomach tumours was relatively low (Dilman et al., 1981). Spiegel et al., 
(1982) reported extremely low levels of high density lipoprotein cholesterol 
in haemotological cancer.
The (3 - lip o p ro te in  cholesterol concentrations were significantly higher
pMrKwH VwitrVi
(P < .001) in the breast cancer group than in^benign breast disease. It was 
also significantly correlated with total 8  -lipoproteins. Cancer cells that 
are replicating continuously require large amounts of cholesterol for the 
synthesis of cell membranes (Gal et al., 1981). This cholesterol could be 
supplied by assimilation of cholesterol from the plasma through uptake and 
degradation of lipoproteins. The association between 8 -lipoproteins and 
cancer can be explained by the fact that they are metabolized at a higher 
rate in cancer cells than in non-neoplastic cells (Gal et al.,1981).
The elevated plasma lipid concentrations were not found to be 
accompanied by increased activity of plasma lipases in the patients with
breast carcinomas. The result of the present study are not consistent with
Hie.
^Basu and Williams (1975  ^ who reported an increased plasma lipase in
patients with breast cancer. This may be explained by 2 factors, both of 
which are due to the lability of plasma lipase during storage. In their study
separated plasma was analysed within 3 days, whereas in the present study
plasma was analysed within more than one to 2 weeks in some samples. An
a
additional factor is the use ofy.different techniques for the measurement of
wvHt
the lipase, ie.,*a colo rimetric method (Beir, 1953) compared a recent 
assay using a diagnostic reagent (Verduin, 1973).
The majority of investigators believe that any effect of nutrition on 
CHD lies in the changes in serum lipids and lipoproteins (Howard, 1981). 
The evidence that elevated serum lipids are one of factors involved in CHD 
is very impressive. The risk of developing CHD is clearly related to 
antecedent blood cholesterol levels (Wallace et al., 1982). Furthermore a 
clear-cut relationship between serum cholesterol and new coronary events 
was established in a prospective study in Framingham (Kannel et al., 1971).
In a nine-year follow up of 3000 men in Stockholm, Carlson and Bottinger
also
(1972) showed that CHDy  ^ increased linearly with increasing fasting 
concentrations of plasma triglycerides^and that the risk was independent of 
plasma cholesterol.
Mortality data from arteriosclerotic and degenerative heart disease 
(AHD) and per capita consumption of total fat, saturated fat, sucrose, 
simple sugars, complex carbohydrates, and protein, and calorie intake^for 
37 countries were statistically evaluated to investigate the possible 
relationship between dietary factors and AHD (Marison, 1970). 
Consumption of total and saturated fats is strongly and positively 
correlated with death rates.
The lipid hypothesis for the development of CHD postulates that 
diets high in saturated fatty acids can results in raised blood cholesterol 
levels.
These in turn link * with development of atheroma (deposition blood 
vessel walls) and hence CHD. In contrast a low intake of saturated fat, 
coupled with an increase in the proportion of fat in the diet containing 
mainly polyunsaturated fatty acids, is thought to reduce CHD.
A number of population groups, however, do not conform to the lipid 
hypothesis. The Israel i  Jewish population i 5  one example (Blondheim et 
al., 1982). They consume a diet which is lower in total fat than those of 
other Western countries ; also much of the fat is high in polyunsaturated 
fatty acids. Although this diet approximates quite closely to dietary 
guidelines, incidence of CHD in Israel is almost as high as in the U.S.A. 
The Masa i tribes of Central Africa who live almost exclusively on milk
drinking up to 4 litres per day have abnormally low serum cholesterol
(\
(135mg/100mp and low^incidence of CHD (Howard, 1981). The milk factor 
which lowers serum cholesterol has not so far been identified. Recently 
Norman (1983) evaluated the epidemiological evidence associating dietary 
lipids, refined carbohydrates and CHD. This led him to suggest an 
alternative hypothesis, namely, that CHD is caused mainly by refined 
carbohydrates.
In Western countries,where mortality and morbidity from^breast
cancer and CHD are high? we can hypothesize that dietary fat
intake is the common underlying risk factor for both diseases.
More correlation studies between these two diseases needs to be
carried out. This may include screening all women with cardiac ischaemia
for breast cancer. The protection enjoyed by premenopausal women 
^  i>\. W\ev\Of>cM*£ all
against CHD is reduced, with mortality rates from myocardial infarction
h vwHk
rising during postmenopause until they eventually approximate^,those found
the
in men (Whitehead, 1981). In Western women, two periods in^life-cycle, 
puberty and menopause, appear to be associated with an increased 
incidence of breast cancer and possible CHD (Hill et al., 1978).
yV\OV>J'lW/
Hormonal changes^ have; , been implicated in breast cancer
and it could be that the changes in lipid concentrations are, in fact, 
secondary to these. There is evidence that breast cancer premenopausally 
and postmenopausal are different diseases (deWaard, 1979) and it is of 
interest that plasma lipid concentrations were higher in postmenopausal 
.subjects'■-W.HK breast cancer. The plasma concentration of 
cholesterol, triglycerides, and low and very low density lipoproteins may 
increase by as much as 20% during the climacteric (Whitehead, 1981).
The concentrations of all plasma lipids with; the exclusion of HDL-
O itcholesterol were significantly higher in post-menpoausal wivvv/
o,S toW>pttY€.A WHV\ WiiU V?JiYvivv^ W^ {cA.^ (>cv^ .
/‘premenopausal A similar trend was shown betweenj(premenopausallij
and postmenopausallii , -  ) Numerous studies indicate
markecj changes in serum lipid concentrations and distribution coincident 
with the period of declining female gonadal activity (Marshal^ 1964). 
During^ menopause, significant increases in serum cholesterol and 
phospholipid as well as in^cholesterol/phospholipid rat io  have been des­
cribed (Oliver & Boyd, 1953;P\^Vv-CV>(Lyj-et_al., 1956). In addition, in this 
study a greater percentage of serum cholesterol is associated with the 8 -  
lipoprotein fraction in postmenopausal cancer patients as compared with 
the premenopausal patients in whom a i proportion of serum 
cholesterol is in the HDL-fraction. Similar findings have been reported
(Heiskei 1 et al., 1961) ~ ,elevation of serum 8 -lipoproteins in
1 v*3 iHi
postmenopausal women as compared premenopausal women.
/\ ehdogehbus and exogenous oestrogens influence lipid metabolism, and
bvm V
as \ disturbance in lipid metabolism is associated withkcancer, much
b U re\ i
interest has been generated in this ^ \ v . t . . Following the menopause, the
extra*-gonadal pathway becomes the sole source of oestrogens (Kirschner et
al., 1982). It seems reasonable to postulate that hyperlipidaemia in
postmenopausal patients is associated with hyperoestrogenism, possibly
leading to chronic stimulation of oestrogen responsive breast tissue.
Another version is the "oestrogen window hypothesis" of Korenman (1980)
which proposes that an increased duration of either of the two normal
periods of anovulation cwftfc^low progesterone/oestrogen ratio (i.e.,
the "windows", namely, the decreased progresterone just before menopause
increases the risk of developing breast cancer.
It IS K y\ o vo yv  that sex hormones and lipoproteins are int err elatedj
the incidence of atherosclerosis and coronary disease is higher in men
than it is in premenopausal women. After the menopause, the relative 
VOOW\q.y\
immunity^to myocardial infarction is to some extent lost (Barr et
al., 1952). Plasma lipoproteins were measured before and after removal of 
fS.Y|ovwied
the ovaries^for temporary palliation of advanced breast cancer. The alpha-
lipoprotein phospholipids and cholesterol increased in all patients
regardless of the type of metastasis (Barclay et al., 1957). Wynn et al.,
(1966) studied the effects of oral contraceptives in lipoprotein metabolism.
The data obtained showed elevated serum triglyceride, cholesterol, low
(X
density lipoprotein and and very low density lipoprotein levels in^cross
sectional study of 1 0 2  women receiving oral contraceptive therapy.
In the present study plasma lipids tended to be higher in the 
both
postmenopausal group in^cancer and non-cancer breast disease.
X the lipid content of plasma increases with age with
the result that the average serum concentrations of cholesterol, 
phospholipid and triglycerides are higher in
postmenopausal women (Furman 1969). The differences in the serum lipid
and lipoprotein patterns of premenopausal and postmenopausal women may
be ascribed to differences in ovarian oestrogen production. Several lines of
evidence suggest that the adrenal glands and not the ovaries are the seat
of origin of most circulating oestrogens in older women (Judd et al., 1982).
The contribution of the adrenal glands to the oestrogen pool could be
through direct glandular secretion or by peripheral conversion of
circulating steroids. Thus, it  seems that the effects of gonadal hormones
on serum lipids may offer an explanation as to why premenopausal and
postmenopausal breast cancer are different diseases. r ,
Wi+Vl +1(6. i irtCicl6.HC6.oj.
The potential relationship of some hormonal patternsyy^ breast 
cancer ' in humans suggests that diet or nutritional status may 
function as modifiers of mammary cry U v\ o^ v'S\$ In women, dietary
modification and life style affect the risk of breast cancer and may alter
onoj-
the hornrm  ^status, while in experimental animals* diet can alter the
incidence of induced mammary tumours (Hill et al., 1977a). In 1975 Chan et
al., reported that female Sprague-Dawley rats fed a high-fat diet (20%
lard) had serum prolactin levels during proestrus-oestrus four to five times
Os.
higher than those observed in rats on/N0.5% lard diet.
There are large gaps in our scientific knowledge concerning the
c\6Uv\V\l- -fcxcf \W&
effects of diet on hormone synthesis and metabolism. © n / \  most
\{\<i bec<\u<&
nutrients participate in ^ citric acid cycle, and ^ acetate is the primary
precursor of all steroids, the potential for interaction between diet,
androgens, oestrogens and prolactin is great (Harper and Grodsky, 1979).
The aromatizing enzymes of fat tissues are capable of converting
androgens to oestro'gens. As pointed by Lipsett (1975), it  is possible that
the production of oestrone in fat tissues is greater among obese
\vi
postmenopausal women thav\^women of normal weight. In
vjowievi
younger the synthesis of oestrogens by the ovaries may depend upon 
critical level of body fatness (Hankin and Rawlings, 1978). Consequently, 
measurements of dietary intake, skinfold thickness, urinary and plasma 
oestrogens among women of all ages may provide further insight 
Concerning the risk factors of breast cancer. Such studies will provide data 
concerning the interrelationships of diet, nutritional status, hormonal 
systems and breast cancer. The results may provide valuable information 
for developing preventive health programmes.
The duct papilloma patients were excluded from the non-cancer 
group because of their relatively high mean plasma lipid levels. More 
investigations need to be carried out on a larger number of duct papilloma 
patients in order to provide meaningful results. The rather higher 
concentration in the duct papilloma patients may be associated with higher
body weight (mean body weight 7 0 + 4  kg, compared 59 + 1kg in the 
other benign disorders). However, the differences in the findings could also 
be due to the fact that the disease, duct papilloma, possesses particular 
characteristic biochemical features, and further work is required to clarify 
this point. Duct papilloma can occur at^v\\j age and should usually be 
removed, partly because of the' ' nuisance value and partly because^on rare 
occasions they may have malignant potential (Baum 1981).
uiith
+  r=0.93s l.'p.'.U/UcI
CHAPTER FOUR :
Prolactin in Breast Cancer
CHAPTER FOUR
Prolactin in Breast Cancer
4.1 Introduction :
Prolactin, a polypeptide hormone secreted by the anterior pituitary 
gland, has been implicated in a wide variety of metabolic processes. 
Although only its role in the control of lactation and gonadal function has 
been established in man, an effect on breast cancer has been suggested. It 
acts directly on the stimulated mammary gland resulting in the initiation 
and maintenance of lactation. The importance of prolactin as a 
stimulatory hormone for breast tissue has been confirmed by the finding of 
specific prolactin-receptors on both normal and cancerous breast cells.
Interest in prolactin as a potential hormone involved in the genesis of 
breast cancer has been heightened by several laboratory and clinical 
observations. Chan and Cohen (1975) found that a high fat diet increased 
prolactin levels and promoted mammary tumours in DMBA-treated rats. 
They hypothesized that a chronic high fat diet would increase the prolactin 
to oestrogen (P/E) ratio in humans, leading to increased carcinogenesis of 
mammary tissues.
Results of studies on the prolactin levels of breast cancery,are 
inconsistent. Kwa et al., (1976) and Boyns et al., (1973). reported no 
differences in prolactin levels between cases and controls. However, Kwa 
et al., (1974) did find higher serum levels in patients with a family history 
of breast cancer. Henderson et al., (1975) found elevated serum levels of 
prolactin in the daughters of patients with breast cancer. Women with 
metastatic breast carcinoma have been reported to have increased levels 
of prolactin when compared with patients without this disease (Rolandi et ,
pecH^v\H
The administration of prolactin suppressing drugs to patients with 
breast cancer has also yielded conflicting reports. Murray et al., (1972) 
reported improvement in 2 of 7 patients with metastatic breast cancer 
following L-dopa therapy, an effective but transient suppressor of prolactin 
secretion in women. A very provocative yet unconfirmed report by two 
independent laboratories (Armstrong et al., 1974 ; Heinonen et al., 1974) has 
provided statistical data suggesting that women who have been chronic 
consumers of the tranquilizer Reserpine W w  a 2- to 6 - fold higher breast 
cancer risk. Reserpine is a well known stimulator of prolactin secretion in 
humans as well as in lower animals.
The liporegulatory influence of prolactin should be considered one of 
its basic functions (Meir, 1977). The finding of raised plasma lipid 
concentrations in this study suggested the present investigation of 
prolactin levels in breast cancer patients.
4.2 Results
The distribution of plasma prolactin concentrations in 94 patients is 
shown in Table 4.1. The results were grouped according to 
 ^histopathological reportw^benign or malignant) and *
reproductive status.
Visual inspection of the data showti- v : a difference in the
distribution of prolactin levels between various groups with a 
preponderance of cases of hyperprolactinaemia (defined as the mean 
exceeding 360 m U / l ) in the group of premenopausal women with breast 
cancer. In both cancer and non-cancer patients the concentrations of 
prolactin were higher in the premenopausal than in the postmenopausal 
patients. The difference between the prolactin levels in cancer and non- 
cancer patients was greater in the pre-menopausal (P < 0 . 0 1 ) than in the 
postmenopausal women (P < .03) (Table 4.1).
Amongst patients with benign disease, premenopausal women had
higher levels of prolactin than postmenopausal women (P < 0.05). The 4
pre-menopausal women with duct papilloma had the lowest concentrations
of prolactin. The prolactin levels in patients with other benign breast
diseases did not differ significantly according to menopausal status. The
premenopausal fibroadenoma and other benign disease^had higher values of
w li h
prolactin in comparison duct papilloma with similar menopausal status.
The number of patients and controls with hyperprolactinaemia is 
shown in Table 4.1. The^e were 9 premenopausal and 2 postmenopausal 
non-cancerous patients with hyperprolactinaemia. All the
hyperprolactinaemio fibroadenoma patients were in the reproductive
The details of breast cancer patients with hyperprolactinaemia are shown 
in Table 4.2. There were 13 premenopausal and 7 postmenopausal breast 
cancer patients with hyperprolactinaemia. A ‘fourfold' or 2 + 2
contingency table were used to calculate the chi square and the results 
showed that there was significant differences (0.05 < P < 0.02) between the 
number of cancer and non-cancer patients with hyperproprolactinaemia.
In cancer patients for whom the lipid profile was available,
PUjwm
correlation coefficients have been calculated between the/prolactin
concentration body weights and various components of the lipid profile
(Figure 4.1). Amongst both pre- and post-menopausal cancer patients there
was a significant correlation between the concentrations of prolactin and
body weight ( P< 0.05 and P< 0.01 respectively) but there was no
graves
correlation between the two measurements in the non-cancer . In
both cancer and non-cancer patients there was a significant correlation (P 
< 0 . 0 0 1  and ~ P< 0.05 respectively) between prolactin and total lipid 
concentrations after, but not before, the menopause. In post-menopausal 
cancer patients the prolactin levels were also significantly ( P< 0.05) 
correlated with plasma levels of triglycerides and free fatty acids. This 
correlation was not present in the premenopausal cancer patients, but in 
them, prolactin levels were significantly ( P< 0.05) correlated with plasma 
cholesterol levels.
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TABLE 4 . 2
D e t a i l s  o f  P a t i e n t s  w i t h  B r e a s t  C a n c e r  A s s o c i a t e d  w i t h  
I n c r e a s e d ^ P r o l a c t i n  l e v e l s  >  3 6 0  m l l / l
a s e  No A g e M e n o p a u s a lS t a t u s
P K S v / i a  
P r o l a c t i n  
L e v e  1 H i s t o p a t h o l o g i c a l  D i a g n o s i s
1 4 2 P r e - m e n o p a u s a l 5 5 2 5 P o o r l y  d i f f e r e n t i a t e d  c a r c i n o m a
I 4 6 i i  i r 3 5 7 2 I n v a s i v e  l o b u l a r  c a r c i n o m a
3 1*6 ii it 2 6 0 4 I n v a s i v e  d u c t  c a r c i n o m a
*i 3 8 ii ii 2 3 2 2 I n v a s i v e  d u c t  c a r c i n o m a
5 *♦9 ii ii 2 2 6 7 I n v a s i v e  - c a r c i n o m a
6 5 0 ii ii 1 8 8 4 I n v a s i v e  d u c t  c a r c i n o m a
7 4 7 ii ii 1 1 6 2 P o o r l y  d i f f e r e n t i a t e d  i n v a s i v e
c a r c i n o m a
8 4 2 i i  n 7 1 5 P o o r l y  d i f f e r e n t i a t e d  c a r c i n o m a
9 5 0 i i  n 6 1 5 P o o r l y  d i f f e r e n t i a t e d  a d e n o
c a r c i n o m a
0 4 2 ii ii 4 3 6 -
1 4 0 •i ii 4 0 9 P o o r l y  d i f f e r e n t i a t e d  c a r c i n o m a
2 4 5 ii ii 3 6 3 -
3 5 2 P o s t - m e n o p a u s a l 3 0 0 8 I n v a s i v e  d u c t  c a r c i n o m a
4 5 4 If II 1 0 0 0 A d e n o  c a r c i n o m a
5 5 6 II II 8 6 2 I n v a s i v e  d u c t  c a r c i n o m a
6 6 7 II II 6 1 8 I n  s i t u  d u c t  c a r c i n o m a
7 5 4 II II 5 8 8 T u b u l a r  c a r c i n o m a
8 5 2 II II 483 Q u a d r a n t  c a r c i n o m a
9 7 2 #l i« 3 7 7 P o o r l y  d i f f e r e n t i a t e d  c a r c i n o m a
0 3 3 P r e - m e n o p a u s a l 9 7 9 I n v a s i v e  d u c t  c a r c i n o m a
PlOvSwW 
PU*^W
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4.3 Discussion
Using a sensitive radioimmunoassay^ it was found that the basal 
plasma prolactin level was significantly higher in women with breast 
cancer than in age-matched controls (women with benign breast diseases).
The present results support the suggestion of an aetiological 
relationship between hyperprolactinaemia and breast cancer. Earlier 
reports by Murray et al., (1972) have shown that postmenopausal women 
with metastatic breast cancer have a higher mean basal serum level of 
prolactin than postmenopausal women without metastatic breast 
carcinoma. On the other hand, Wilson et al., (1974) using a homologous 
radioimmunoassay, reported normal levels in both primary and metastatic 
cancer ; however, the ages of patients and controls were not specified. 
Be rle and Voigt (1972) reported only that more cancer patients than 
normal controls had "measurable levels" of prolactin, implying that 
prolactin concentrations were higher in the cancer patients ; this was true 
in all age ranges.
Results of studies on prolactin levels of breast cancer patients have 
been inconsistent. There is no obvious explanation for normal prolactin 
levels seen in some breast cancer patients, nor is there a clear-cut 
correlation of this finding with the stage of the disease or the clinical 
course. It is therefore justifiable to say that some human breast cancers 
are prolactin dependent. Kwa et al., (1976), and Boyns et al., (1973) 
reported no difference in prolactin levels of cases and controls. However, 
Kwa et al., (1974) did find higher serum levels in patients with a family 
history of breast cancer. Henderson et al., (1973) found elevated serum 
levels of prolactin in daughters of patients with breast cancer. Murray and 
Sarfaty (1974) have reported higher serum prolactin levels in women with 
advanced cancer of the breast.
The present study has shown a clear-cut continuous linear decrease of
mean prolactin levels with age in cancer and non-cancer patients.
Accordingly, dividing patients into premenopausal and postmenopausal
has shown that the prolactin levels were lower in the post
menopausal '• It appears, therefore, that prolactin concentrations
were higher in the great majority of pre-menopausal cancer and non-cancer
patients. Circulating levels of prolactin in post-menopausal women are
usually lower than in women of reproductive age and this may be due to the
decrease in ovarian oestrogen secretion, and possibly, antagonism
is
between gonado- trophin and prolactin secretion such as /\ found in
experimental animals (Ben David et al., 1971). The steady decrease in mean
prolactin levels of women with age was noted by Vekemans and Robyn
(1975). ' , . . , ' p-Vkie i v\c t cA CQ.
The difference between/vbreast cancer in nulliparous and
other women is well known (Horrobin, 1973). When pregnancy occurs
subsequent to treatment of human breast cancer, the 5-year survival rate
is significantly improved. Pike et al., (1979) have presented preliminary
ifs)&w\ev\
evidence that prolactin levels are lower in parous than in nulliparous, and 
his finding was confirmed by showing that nuns and their nulliparous sisters 
have early morning prolactin levels some 35% higher than do their parous 
sisters of the same age (Yu et al., 1981).
Prolactin is widely regarded as a possible major factor in mammary 
carcinogenesis (Van Der Gugten and Ver Straeten, 1973). However, it is 
possible that an abnormal hormonal environment could alter the sensitivity 
of mammary epithelial cells to the growth promoting effect of prolactin* 
which might then lead to dysplasia and eventual neoplasia. Therefore, it 
seems that not only women with breast cancer have a high resting blood 
level of prolactin, as our results demonstrate, but also that a raised level 
of prolactin per se is harmful to the mammary epithelium.
Previous studies in the rat have demonstrated that dietary fat intake 
affects the development of spontaneous mammary tumours (Hopkins et al„ 
1977 ; Carrol and Hopkins, 1979). Moreover, rats receiving a high fat diet 
have higher circulating prolactin levels during proestrus-estrous, but not 
during metoestrus-di^strus, than animals fed a low fat diet (Hill et al., 
19^). It was shown earlier in the present study that plasma lipids were 
higher in patients with breast cancer. In the extension of this study, we 
have found a correlation between circulating prolactin levels and body 
weight. In the postmenopausal patients there was also a significant 
correlation between plasma prolactin and total lipids, the latter being 
contributed to by the high levels of triglycerides and free fatty acids.
Prolactin appears to be the principal hormone Ccmtrollivvj ■ fat stores 
(Meir, 1977), - has been shown to cause a marked increase in fat stores in
fish, birds and mammals within one week after receiving daily injections. 
Prolactin increases the lipoprotein lipase activity of the rat mammary 
gland. Thus, the overall effect of prolactin is to divert fatty acids derived 
from fat ingestion from body stores to the mammary gland.
Serum total cholesterol and triglyceride levels were determined in 47 
women with prolactinoma and in 84 age matched control women. The 
mean levels of serum cholesterol and triglyceride were significantly higher 
in patients than in controls (Pelkonen et al., 1982).
In summary, prolactinoma is associated with metabolic abnormalities 
characterized by hyperlipidaemia. The question is whether prolactin 
increases circulating plasma lipids or vice versa.
In the premenopausal cancer patients this significant correlation of 
the prolactin with total plasma cholesterol levels could be related to the 
fact that prolactin is responsible for maintaining cholesterol esters in both 
the ovary and testis (Armstrong et al., 1970).
Our results are in agreement with the suggestion of a significant role 
for prolactin in human breast carcinogenesis. It would clearly be of 
interest to follow the response of tumours to therapy aimed at lowering 
prolactin levels in those patients with hyperprolactinaemia. EUv&v\ patients 
with benign breast disease also had prolactinaemia and it will be of interest 
to continue to monitor plasma prolactin levels in these patients and to 
ascertain whether they, too, develop cancer.
CHAPTER F IV E  :
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CHAPTER FIVE
Metabolic Response to Trauma
5.1 Introduction
Trauma is the leading cause of death in the United States (U.S.) 
among the population under 30 years of age (Curreri, 1981). Traumatic 
death ranks third in incidence among all age groups and accounts for a very 
significant financial loss to society when one considers expenses associated 
with prolonged hospitalization, temporary and permanent disability, and 
days lost to the labour force.
There is a rising incidence of hip fractures in the United Kingdom 
(U.K.) (Wallace, 1983). The rise was greatest for women over the age of 75 
years. The incidence of hip fractures would reach epidemic proportions. 
There is considerable evidence that osteomalacia in the elderly may be an 
important contributory factor in the occurrence of fracture of the femur. 
Exton-Smith et al., (1966) showed in their dietary studies of elderly women 
that dietary deficiency of vitamin D causing osteo malacia may be an 
important factor in the production of skeletal rarefaction or osteoporosis.
The surgery carried out for fracture patients is intended to relieve 
pain, increase mobility and enable the patients to enjoy the greatest 
possible degree of independence subsequently. It is vital to mobilise the 
patient as quickly as possible after surgery. Elderly patients with 
fractures are best treated by immediate restoration of function. Where 
bone continuity cannot be safely restored at once, as in femoral neck, 
replacement is the best treatment.
Immediately after the operation, the body's major source of energy is 
fat. The carbohydrate, stored in the liver in the form of glycogen, is 
rapidly utilized and lasts only a few hours unless it is replaced. The fat 
stored in the adipose tissue, in the form of triglyceride, is then mobilized 
and broken down by lipolysis. It then enters the blood as free fatty acids 
and glycerol. The lipolytic process is regulated by triglyceride lipase. The 
activity of this lipase appears from studies on rat fat^to be controlled by 
3,5 - cyclic AMP in adipose tissue. This also applies to human fat as 3, 5- 
cyclic AMP appears to have a key role in regulating the lipolytic process in 
man (Carlson, 1970). Compounds known to be lipolytically active in human 
fat are the catecholamines, glucagon, thyroxine and methylxanthines.
Inhibitory compounds of physiological importance are insulin and 
prostaglandins.
Recently there has been increased interest in the response of plasma 
constituents to trauma such as surgery or myocardial infarction. The
changes in plasma protein levels have an importance in view of the
relationship between nutritional status of critically ill patients and
mortality. Malnutrition is frequently found in surgical patients in hospital 
(H ill et al., 1972) where it can play a vital role in the rate and eventual 
recovery of a patient. In a study in elderly women with femoral neck 
fractures^Older et al., (1980) showed that the mean intake of protein, 
energy, vitamin D, riboflavin, vitamin C, thiamine and niacin fell short of 
the recommended allowances.
During the past two decades remarkable improvements have been 
made in the care of the traumatized patient. Nevertheless more complex 
metabolic problems are being encountered. The difference in the 
experience of such problems on both sides of the Atlantic is striking. In
the U.K., with its low incidence of serious interpersonal violence, the 
majority of major trauma is musculoskeletal, consequently the principal 
problems are those of muscle wasting and of cardiac and respiratory 
systems. In contrast, surgeons in U.S.A. have to manage many visceral 
injuries and their complications caused by gunshot wounds of the chest and 
abdomen.
The metabolic response to trauma has not yet been researched in 
detail and it is becoming increasingly clear that this is a subject of great 
importance. It has been known for some years that protein metabolism is 
altered due to trauma and recently research has shown that lipids and 
lipoprotein levels in the plasma are also affected.
Investigations of changes in fat metabolism associated with injury are 
relatively limited and most of the recent studies have been done on 
patients following myocardial infarction. Moisson et al., (1980) have shown 
that the concentration of total lipids, triglycerides, and cholesterol levels 
decrease significantly during the first hours after an acute myocardial 
infarction.
In view of our interest in plasma lipids and the^availability of patients 
after mastectomy, it \S to be of interest, particularly in view of the 
lipid data available, to study the effects of mastectomy on plasma lipids. 
A further group of patients having a different type of surgery, namely 
repair of femoral neck fracture were availably and the blood lipids on these 
patients were also studied.
5.2 Patients and methods
Details of the patients studied and the methods used in these investigations 
have been described in chapter 2.
5.3 Results
5.3.1 Effect of mastectomy on plasma lipids :
Pl^ SYvi 0\
The concentration of total^lipids was lower on the second day after 
operation and remained low on the seventh day (Table 5.1). However, by 
28 days>the concentration had returned to the preoperative level. The 
concentrations of total phospholipids, triglycerides, total cholesterol, $ - 
lipoprotein and $-lipoprotein cholesterol had also fallen below the 
preoperative value by the second post operative day. The concentrations
o
of total cholesterol, total 8 -lipoprotein and 8-lipop rtein-cholesterol 
remained below the preoperative value at 28 days. In contrast the 
concentrations of total phospholipids and triglycerides had almost
the preoperative value by 7 days. The concentration of HDL-cholesterol 
rose progressively to the 28th day after operation and that of free fatty  
acids had risen significantly by the second day and remained at almost the 
same value through to the 28th day. Lipase activity was not affected by 
surgery.
5.3.2. Effect of surgery on plasma lipids in breast disease patients :
The whole group of patients with breast disease was separated 
according to the nature of the disease (Table 5.2). The effect of surgery on 
plasma lipids was shown by comparison of the preoperative and 28 days 
postoperative values in the different groups of patients.
The total lipids and triglycerides in all groups Of patients and 
phospholipids in the cancer and duct papilloma patients returned to the 
preoperative value by 28 days after surgery. However, during the
same period in the non-cancer group the total phospholipids rose 
significantly 28 days after surgery. In each group of patients surgery had 
resulted in a significant fall in the concentration of total cholesterol and 
total 8 -lipoproteins. The HDL-cholesterol rose significantly in all groups 
of patients. The concentration of free fatty acids was significantly higher 
at 28 days in the cancer patients but was not affected by surgery in the 
non-cancer or duct papilloma patients.
5.3.3. Patients Undergoing Orthopaedic Surgery :
The plasma lipids for the three sampling days in the two groups of 
patients having orthopaedic surgery are shown in Table 5.3.
In the patients who had elective surgery the total lipids, total
cholesterol and triglycerides fell significantly by the second postoperative
day. However, during the same period the HDL-cholesterol and HDL-
cholesterol/total cholesterol ratio rose significantly. Following the second
postoperative day the total lipids and total cholesterol rose slowly up to
VyUVC
the second week, but triglycerides rose^rapidly. In the emergency group the 
total lipids and total cholesterol rose gradually post-operatively, but the 
triglycerides rose signficantly by the seventh postoperative day and the 
level continued to be higher 2 weeks after surgery. However, in the 
elective group the triglycerides returned to the preoperative value by the 
seventh postoperative day. In the elective surgery group^the concentration 
of total cholesterol -£-<?vIU lvy ' . •
postoperatively , but in the emergency surgery group the level 
procjY'e^ iveJvj seventh day and by the second
— x It U —
week the value • enx-t* 4s ecov\cl poSVo p'i'f^Hve <^c\tj
In the elective surgery group the HDL-cholesterol/total cholesterol ratio 
rose significantly then fell away gradually until by 14 days the value was 
not significantly different from the preoperative value. However, in the 
emergency group the value significantly by the seventh day and
returned to the preoperative values by 14 days.
5.3.4 Plasma Lipids in Females Undergoing Surgery for Treatment of 
Femoral Neck Fracture and Breast Cancer :
The concentrations of total lipids, triglycerides and total cholesterol 
weY? lower on the second postoperative day in cancer and elective surgery 
groups. However, the total lipids and total cholesterol in the cancer 
patients remained the same by the seventh day whereas after the elective 
and emergency orthopaedic surgery the values rose slowly postoperatively. 
The triglycerides in each group of patients continued to rise slowly after 
the second day. In the cancer patients, the HDL-cholesterol and HDL- 
cholesterol/total cholesterol ratio y continuously following
surgery, whereas in the elective surgery group the HDL-cholesterol 
remained at the same as the second postoperative day and dropped after 
the seventh day (Table 5.4).
In the emergency surgery group the HDL-cholesterol and HDL- 
cholesterol /to tal cholesterol ratio were not affected by surgery .{.TdvIoU ^-4*)
m u L u  2 . 1  ; u i i c u l  ui  ridsuet;tomy on n a s m a  u i p i a s
( V a lu e s  a r e  mean + SEM)
Pre-operat i ve
P o s t - o p e r a t  i v e
2 days 7 days 28 days
Total Lipids 
mg/100ml
1248 
+ 62
1 0 0 5 ™ *  
+ 45
1004**** 1188
+ 44 + 54
Total Phospholipids 360 
mg/100ml + 13
317 
+ 16
376 
+ 14
368
T riglycerides  
mg/100ml
178 
+ 3
165* 
+ 4
I80 
+ 3
183 
+ 3
Total Cholesterol 280
mg/100ml + 8
238 
+ 6
2 3 ^ ***  
+ 5
2 3 8 .......
+ T
HDL-Cholesterol 
mg/100ml
53 
+ 2
59 
+ 2
64.*** 
+ 2
71 
+ 2
HDL-Chol esterol_____
Total Cholesterol ra tio  20
+ 1
25 
+ 1
28 31 
+ 1
Total $-L*ipoproteins 615 
mg/100ml ’ + 1 6
498 * * * : 
+ 17
484
+16
4 9 8  
+ 16
6“ -^i poprotei n 211
cholesterol mg/lOOml + 6
1 74 - 
+  6 *
x x x x
171“ 
+ 6
1 7 4 * * *  
+ 5
Free Fatty Acids 
meq/l
1.10  1 .22  xw's
+ 0.39 + 0.048
1 .21™  1 .2 7 ”
+ f l .004 ±0.044
Lipase i 'U . / l 278 
+ 3
282 
+ 2
289 
+ 2
279 
+ 3
Value s ig n ific a n tly  d iffe re n t from pre-operative value shown: 
* * * *  when P < 0.001
* * *  when P < 0.01 
* when P < 0.05.
-1 Id”
Table 5.2 : Effect of Surgery on Plasma Lipids in Breast Disease Patients
Values are mean + SEM
Preoperative Postoperative 
(28 days)
Total Lipids (mq/lQQnrl)
Cancer 
Non-cancer 
Duct papilloma
Total Phospholipids (mq/lQQml)
Cancer 
Non-cancer 
Duct papilloma
Triglycerides (mg/lOOml)
Cancer 
Non-cancer 
Duct papilloma
Total Cholesterol (mg/lOOml)
Cancer 
Non-cancer 
Duct papilloma
HDLCholesterol (mg/lOOml)
Cancer 
Non-cancer 
Duct Papilloma
Total B 'Lipoproteins (mg/lOOm)
Cancer 
Non-cancer 
Duct papilloma
Free Fatty Acids (meq/l 1
Cancer 
Non-cancer 
Duct papilloma
1248 +62 
880 + 25 
1095 +102
360 + 13 
296 + 11 
268 + 17
178+3  
144 + 2 
151 + 6
280 
224 + 6  
268 +4
53 + 2 
6 7 + 2  
6 4 + 4
615+16  
470 + 13 
508 + 36
1.10+0.039  
0.70 +0.001 
0.70 + 0.029
1 1 8 8 + 5 4  
900 + 19 
1124 +147
368 + 13 
3 1 8 * * *  + 13 
300 + 16
183+ 3  
148+7  
154 + 6
2 3 8 * * * * +  7 
2 0 2 * * *  +5  
2 1 8 * * *  +18
7 1 * * * * + 2  
72* +2
7 7 * * *  + 4
4 9 8 * * * *  +16  
4 2 6 * * *  + 14
454* + 40
1 .2 7 ** *  +0.044 
0.70 + .001 
0.72 + 0.027
Values significantly different from preoperative values shown : 
* * * *  wher, P < 0 . 0 0 1  
* * *  wher + P< 0.01 
*  wher t P< 0.05.
T A B L E  5 - 3  * P l a s m a  L i p i d s  i n  P a t i e n t s  U n d e r g o i n g  E l e c t i v e  S u r g e r y  f o r  
F e m o r a l  H e a d  R e p l a c e m e n t  A n d  E m e r g e n c y  S u r g e r y  F o r  F e m o r a l 
N e c k  F r a c t u r e  ( V a l u e s  a r e  m e a n  +  SEM
Pre-operative P o s t -  o d e r a t i v e (davs) .
2 7 14
Total LiDids (mq/lOQmL)
Elective m 649 * * * * 7 3 0  * * * * 8 0 2  *
+ 48 ± 42 ±  50- ± 36
Emergency 
T ria lvcerides (mg/1 0 Oral)
770 
±  75
807 
± 55
875 ++++ 
± 5 6
Elective 135 104 * * * * 13$ 131
± 8 ± * + 9 + 13
Emergency
Total Cholesterol (ma/lOOml)
145 
± 6
1 64 +++ 
+ 6 -
1 8 1  ++++ 
+ 8
Elective 233 14 5  * * * * 1 7 6 * * * 2 0 6  * * *
+ 8 + 8 - + 1 2 ± 1 0
Emergency 
HDL-Cholestero (ma/1 0 0 ml)
150 
± 6
159 
± 6
167+ 
±  8
Elect i ve 85
j- j-
98 8 8 84
+ 6 + 6 + 8 + 4-
Emergency
HDL-Cholesterol
Total Cholesterol ra 1 0
65 
+ * ■
54+++ 
+ 3
68 
±  4
Elect i ve 36 68 * * * * 51 * * * 42
+ 2 + 4 + 5 + 4
Emergency 44 
±  3
35++ 
+ 2-
42 
+ 3
V a l u e s  s i g n i f i c a n t l y  d i f f e r e n t  f r o m V a l u e s -  s i g n i c a n t l y f d i  f f e r e n t  f r o m
p r e o p e r a ' t  i v e  v a l u e s  s h o w n  : s e c o n d  p o s t o p e r a t i v e  d a y  s h o w n  :
* « * *  w h e n  P < 0 . 0 0 1 + + + +  w h e n  P < 0 . 0 0 1
* * *  w h e n  P < 0 . 0 1 + + +  w h e n  P < 0 . 0 1
* *  w h e n  P <  0 . 0 2 + +  w h e n  P < 0 . 0 2
*  w h e n  P < 0 . 0 5 - +  w h e n  P <  0 . 0 5 .
elective  bUl MCI Y 1 Ur I dim r d I llCdU i c p I g^cmci i l > aim gmu i g i^ lujf
s u r g e r y  f o r  f e m o r a l  n e c k  f r a c t u r e  
________________________________________ ( V a l u e s  a r e  m e a n  +  SEM)_____
Pre-operative P o s t -  o d e r a t i v e (days!
2 7 14
Total Lipids (mq/lOOml)
Cancer 1248 1005 * * * * 1004****
± 6 2 + *5 ±  44
Elective 8 5 8 6 6 6  * * * * 747 * * * 842
± 72 ± 5 8 ± 7 5 ±  32
Emergency - 7 6 0 817 8 6 8
±  57 + 6 8 + 67
Trig lycerides (mq/lOOml)
Cancer 178 165 * 1 8 0
+ 3 ±  ** ± 3 -
Elective 134 107*** 137 138
+ 1 1 ± 7 ±  13 ±  1 6
Emergency - 144 1 6 1 176
+ 7 ± 7 ± 8
Total Cholesterol (mq/lOOml)
Cancer 2 8 0 2 3 8 * * * * 234 * * / w C
±  8 + 6 ± 5
Elect i ve 237 1 5 3  * * * * 187**** 2 1 0 *
+ 1 0 + 7 + !5 + 2 1
Emergency - 1 5 0 1 6 2 1 6 6
+ 7 + 7 + 9
HDL-Cholesterol (mq/lOOml)
Cancer 53 59 * 64 * * * _
±  2 ±  2 ± 2
Elect i ve 91 97 80*** 80 * * *
±  7 ± 7 ±  5 + 4
Emergency - 67 53 67
+ 5 + 3 + 4
HDL-Cholesterol . _
Total Cholesterol ra 10
Cancer 2 0 25 28 * * * -
+ 1 ± 1 ± 1
E lective 39 63* * * 44 40
± 2 ±  5 + 5 +. 5
Emergency - 45 33 42
+ 3 ± 2 + 3
V a l u e s  s i g n i f i c a n t l y  d i f f e r e n t  f r o m  p r e - o p e r a t i v e  v a l u e s  s h o w n  :
* * * *  w h e n  P < 0 . 0 0 1  * *  w h e n  P < 0 . 0 2
5.4 Discussion
Four groups of patients have been studied in this investigation. One
group had a benign condition, benign breast disease, and served as a control
for patients with breast cancer. Differences between these patients before
operation are due to the presence of cancer as discussed in previous
chapters. Differences after operation are likely to result from the
iw
different operative procedures. Mastectomy has a common feature^that it 
involved more tissue disruption, it  differs in its severity, ' ' ' from
excisional biopsy, lumpectomy and microdectomy where there is less tissue 
handling. The third and fourth group of patients also had orthopaedic 
surgery for treatment of femoral neck fractures. Two surgical procedures 
were used namely femoral head replacements (third group) and internal 
fixation (fourth group), which are relatively simple and allow immediate 
mobilisation of the patient.
In the study of each group of these patients there were some 
similarities between the changes'll lipid profiles. These similarities may 
represent the general response to trauma in plasma lipids. The 
concentration of total lipids, triglycerides, and total cholesterol fell 
significantly on the second postoperative day in the elective orthopaedic 
and breast cancer patients. In the latter group the level of total 
phospholipids, 3-lipoproteins and 3-lipoprotein cholesterol also fell 
significantly on the second postoperative da^. It is likely that these 
changes were due to postoperatve haemodilution. The retention of sodium 
after injury is one of the most constant features of the metabolic response 
to trauma and is mediated through the release of aldosterone. It begins 
immediately after injury, reaches its maximum by the second day, and lasts 
for 4-6 days or even longer, depending on the age of the patient and on the
severity of trauma (Walker and Johnston, 1971). Retention of sodium is 
accompanied by retention of water.
In breast disease patients the concentrations of total lipids in the 
plasma four weeks after operation were not significantly different from 
the preoperative values. In the breast cancer patients^ intermediate 
samples showed a fall in the concentration. By the 14th day after surgery,
the total lipid concentrations in the plasma of the elective orthopaedic
with
surgery patients were comparable those of basal preoperative values.
However, total lipid concentration showed a tendency to rise which y?-Hvvns 
4i\(L
to/f preoperative value. This change was not correlated with changes in
other lipid profiles. The alteration in total lipid plasma concentrations in
the immediate postoperative period may be due to . 'A role as energy
proViiiqb It appears likely that the increased concentration of free fatty
acids (FFA) in plasma after mastectomy is due to an increased rate of their
mobilisation from adipose tissue. The increased levels of FFA in different
conditions are generally due to the mobilisation into plasma
and seldom due to a reduced fractional turnover rate in plasma. Another
explanation is that during starvation after operations, trauma, etc., the
main source of energy is the body fat (Wretlind, 1976). Lipolysis is a major
pathway for the metabolism of the fat and for the supply of fatty acids to
the blood stream. The largest site of lipolytic activity is in the adipose 
e.*-V«.V}S>ivK }
tissue with its / stores of triglycerides. = ts importance is due to
fatty acids being the direct metabolic fuel for tissues during starvation.
Interestingly, several authors have reported that plasma triglycerides
rose significantly in response to trauma (McNamara et al., 1972 ; Lepisto,
1976). This was clearly true in the present study. Lepisto (1976) studied the
blood lipid changes in 43 patients and found that the serum triglyceride
concentrationiTose in four days while a small fall in the concentration of
cholesterol and phospholipids was noted in 8 of the patients who were
diagnosed as having ’fat embolism syndrome1, an uncommon disease 
associated with obstruction of the microcirculation by fat globules. 
Triglycerides are composed of one molecule of glycerol bound by ester 
linkages to three molecules of fatty acids. Most triglycerides are derived 
from glucose^and under the influence of andrenaline^ glucagon or growth 
hormone (in response to trauma) breakdown of triglyceride into glycerol 
and FFA occurs these are released into blood stream and are available 
as a tissue fuel. G  perationsin the benign breast disease patients did not 
affect the plasma FFA level. his may be due to the smaller degree of 
trauma in the$e ' p e o p W  ,3 ^:, vi . Birke et al., (1965) has 
reported that the FFA were elevated in burn patientsy the more 
pronunced the trauma^the more prolonged elevation. By two days after
operation, the FFA continued to rise parallel to the levels of total lipids
a
and triglycerides in the m stectomy patients. The FFA level, however, 
increased to the preoperative value by 28 days after operation. This may be 
because the effects of trauma differ in lipid profiles.
It is not clear if  ' . elevation of the plasma FFA level after trauma 
is useful or harmful to , patients. Studies in dogs with high plasma FFA 
levels induced by injury have shown that a raised level of plasma FFA was 
associated with increase in ; triglyceride content of the liver. 
Moreover, this increase in liver triglyceride was proportional to the rise of 
FFA level (Carlson, 1970). These findings, coupled with the observation 
that patients who die after severe trauma very often have extremely fatty  
livers (Carlson, 1970) has made it desirable to prevent the elevation of 
plasma FFA levels which follows injury. Allison et al., (1969) reported that 
preoperative infusion of glucose lowered the plasma level of FFA. During 
operation, however, the basal level of FFA was elevated and the stimulus 
of operation caused a continuing rise in spite of glucose infusion.
In the present series of investigations the plasma total cholesterol
fell postoperatively. However, in the orthopaedic surgery patients two
days after operation, the level rose progressively and the biggest rise was
S till
14 days after operation in the elective group,^yet i t  vas^below the 
preoperative value. This suggests that the fall in plasma total 
cholesterol concentration is a feature of a general response to injury. 
However, . rise in intermediate values of the orthopaedic surgery 
patients may be because of the degree and type of trauma having a 
different effect on lipid profiles. ' -  The
significant fall in total cholesterol concentration was due to a 
corresponding fall in the concentration of 3-lipoprotein which transports 
cholesterol around the body. Barclay and Skipski (1975) have reported that
I
patients with breast carcinoma have high levels of 3-lipoprotens which 
decrease after surgery. Cotton (1970) has shown that the general trend for 
plasma cholesterol was towards lowest levels about the end of the first 
week of myocardial infarction, similar to the results obtained in this study. 
The fall in plasma total cholesterol could perhaps be due to release of a 
tissue enzyme which inhibits hepatic biosynthesis of cholesterol or 
enhances its breakdown. Another possibility is that the protein moiety of 
3-lipoproteins is either synthesized at lower rate following surgery, or that 
there is excessive catabolism. Increased rates of elimination of the 3- 
lipoproteins from the plasma compartment by leakage and exudation of 
lipoproteins through the wound area, might also be involved in causing the 
decreased concentration. The latter condition cannot, of course, hold for 
other stress conditions such a5 myocardial infarction or inflammatory 
diseases. Werner (1969) in his observation of serum protein changes 
following partial gastrectomy noted a fall in total proteins mainly due to
decreased albumin in the first three postoperative days, accompanied by a
fall in both alpha and beta lipoproteins. He suggested that these changes
are due to the loss through exudation # the wound with temporary failure
of the liver to replace the protein loss. The 3-lipoprotein cholesterol
showed the same trend as total 3-lipoproteins. The fact that the level of
3-lipoproteins was higher in patients with cancer than in those with benign
breast disease suggests that the high level is associated with breast cancer,
and this would seem to be confirmed by the reduction in concentration
which follows removal of the tumour.
Birke et al., (1965) noted that in burn patients there was a marked fall
in cholesterol and both alpha and beta-lipoproteins starting on the first day
and reaching its greatest value on about the tenth day. The clearest
evidence that metabolic response to injury is proportional to the degree of
injury has been obtained in studies on burned patients, in whom the area of
body surface affected gives a measure of the extent of L . /. Watson et
al., (1963) found a significant fall in plasma cholesterol following
myocardial infarction with the lowest levels occurring on*6th and 9th days
after infarct^ and that the levels began to rise after the 9th day,^reaching
' the pre-infarct levels at 21 days/ _ ,
In the present investigation the HDL-cholesterol concentration rose
progressively to the 28th day after operation, in breast disease patients,
f-fcVi'tvfts «
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whereas in the elective orthopaedic surgery^ it remaim the same at the
pjLcl Ltj
second postoperative day and drop  ^ ' the seventh day. This is likely to 
be due to the type of surgery, and that^elderly surgical patients are more 
prone to postoperative complications (fat embolism and infection).
/  . Coronary heart disease (CHD) has been linked to low levels of
HDL-cholesterol (Anderson et al., 1978) and raised levels of LDL, VLDL,
total cholesterol and triglycerides. Miller and Miller (1975) demonstrated 
that as the body cholesterol increases, the plasma HDL level decreases. 
HDL facilitates the uptake of cholesterol from peripheral tissues and its 
transport to the liver for catabolism and excretion. Plasma HDL levels are 
depressed in several conditions associated with an increased risk of CHD, 
and subjects with existing CHD have lower HDL than healthy subjects. 
Therefore any reduction in the plasma HDL-cholesterol may accelerate the 
devleopment of atherosclerosis and hence CHD, by impairing the clearance 
of cholesterol from the arterial wall.
The HDL-cholesterol in the breast disease patients rose significantly
o
f rm the first to the fourth sample. These results are apparently agreeable 
with those of Barclay et al., (1959) who reported an increase in a 
corresponding lipoprotein fraction, the alpha-lipoproteins, following radical 
mastectomy in eight patients with breast cancer. ; .
■ - ' ,  ^ ^ , . The rise correlated
with the downward fall in plasma cholesterol and beta-lipoproteins. This 
may also represent a protective factor from CHD risk. The precise 
mechanism whereby trauma leads to higher plasma concentration of HDL, 
and to other changes of lipoproteins is currently not known. It seems 
probable that surgical stress leads to increased muscle and adipose tissue 
lipoprotein lipase activity which, in turn, leads to lowered plasma 
triglyceride concentrations and ultimately to increased HDL concentration. 
The enzyme lipoprotein lipase, which is involved in the hydrolytic 
clearance of triglycerides from the blood stream, has been reported to 
have increased activity in the adipose tissue of trauma patients (Robin et
In the cancer patients there was a highly significant rise in HDL- 
cholesterol/total cholesterol ratio following surgery, and the level 
continued to rise to the end of the fourth week. The same trend was shown 
by the benign breast disease patients, whereas in the elective orthopaedic 
surgery patients the level by the second postoperative day but was 
comparable to the preoperative value by the 7th postoperative day. This 
indicates that the major effect of trauma was on the lipoprotein molecules 
(HDL) and differs with the type of injury. The dissimilarity of the effect of 
trauma in the breast disease and orthopaedic patients may have been 
better explained by subfractionation of total HDL into HDL2 and H DLy  
Subfractionation may be of value in determination of^prognosis of surgical 
procedures. Women who had normal values of HDL^ when first examined 
made more satisfactory responses to the mastectomy procedures, and 
maintained higher serum levels of HDL2 during postoperative periods in 
which serum was analysed several times for lipoprotein^Barclay et al., 1959 
and Barclay et al., 1964).
The alteration in HDL cholesterol is the most important finding, as a 
low level of this lipoprotein has been found to be three times more 
predictive of CHD than a raised cholesterol level (Vergani et al., 1978).
may be a protective factor from CHD as their preopertaive lipid values
Y ^he stress of surgery^acts as a stimulus 
in such patients for the release and removal of cholesterol from peripheral 
tissues.
The total phospholipid levels decreased during the first 48 hours after
mastectomy then increased slowly and were restored to the initial value
after 4 weeks. In the microdectomy patients the phospholipids were
restored to the preoperative levels within four weeks. However, during the
same period the phospholipids in the non-cancer patients increased, and
o
this may be due to the differences in pathlogical state and type of 
operation. This rise in the total phospholipids was paralleled by a 
corresponding rise in HDL-cholesterol. This indicates that the major 
effect of trauma was on the entire lipoprotein molecule (HDL) which is a 
major carrier of phospholipids in plasma. In an earlier study (Johnson and 
Wadstrom, (1956) the lipid and lipoprotein pattern was studied after 
experimental trauma in the rabbit. The results of their investigation 
showed trauma to be followed by an increase in the glycerides and 
phospholipid levels of the serum.
In the present study, plasma lipase activity was not affected by
surgery. Herndon and Riseborough (1978) reported in their study of
as’
fracture patients that lipase changes were not significant as those of FFA. 
The lipase activity was higher only in patients who develop hypoxia.
A possible clinical significance of this study is that firstly, low levels 
of HDL-cholesterol may be a risk factor for CHD, and lipid metabolism 
studies may be of importance in deciding the type and degree of surgery 
according to lipid concentrations in plasma. It is important that patients 
being investigated for hyperlipidaemia should have blood samples taken at 
least 8 weeks after an injury such as myocardial infarction or surgery. 
Falsely low results may be obtained otherwise, as the patient's HDL- 
cholesterol has been affected by trauma, as well as total cholesterol levels.
The dissimilarities between the orthopaedic surgery and breast disease 
patients may be due to different nutritional status and age. Malnutrition is 
frequently found in surgical patients in hospital (Hill et al., 1972) where it 
can play a vital role in the rate and eventual recovery of patients. A study 
carried out by Older et al., (1980) in the same orthopaedic patients as in the 
present study showed that their nutrient intake was inadequate.
There was difference in the sampling opportunities because in the 
benign breast disease group no blood samples were obtained in the 
immediate postoperative period  ^ this group was discharged from hospital 
within 24 hours and there was no opportunity of collecting ilu iY ]
Another difficulty encountered in this study, where blood levels were
cU.'HvwTivu o\
being . / '  following admission to hospital, is that no base line could
be measured. Most of the subjects included were admitted to hospital for 
orthopaedic surgery as emergency cases. An attempt was made to 
overcome this difficulty by including patients undergoing elective surgery 
where preoperational values were obtained and used as base line data. A 
larger group would have yielded better results for correlation,* nine 
subjects are not enough to show statistical significance between the 
groups.
However, the fact that there were 20 women and 7 men reflects the 
finding that there are higher numbers of occurrences of fractured femur 
amongst elderly women than men. There is a rising incidence of hip
fractures in the U.K. The rise is greatest for women over the age of 75
qV\ cl
(Wallace, 1983). The rate of fracture of the femur rises with age, andy-.
gfc\pV\ is
/.generally more steeps in women than in men.
titve
In conclusion, the observations presented suggest^that the presence of 
cancer has a significant effect on the general pattern of plasma lipids, 
mainly the decrease of plasma lipoproteins. With regard to the effects of 
surgical operation on plasma lipids and lipoproteins, the present findings 
suggest that different surgical procedures could have different effects
V\ f-
depending on their /* and nature. In general, it seems that 
operations^ such as mastectomy or femoral neck fracture fixation are 
associated with a decrease in total lipids, triglycerides, and total 
cholesterol in the immediate postoperative period. However, the same 
operations differ in their effect on HDL-cholesterol and this difference 
could be related to the nature of operation and clinical state of the 
patient.
CHAPTER S IX  :
General Discussion and Conclusions
CHAPTER SIX 
GENERAL DISCUSSION AND CONCLUSIONS
£.1 General Discussion
The high plasma lipid concentrations observed in breast cancer 
patients when compared with patients of similar age with other breast 
diseases could have resulted from a high intake of dietary fat. If  this was 
so, the data presented would provide some support for the epidemiological 
studies suggesting correlation between dietary fat and breast cancer. 
The United Kingdom (U.K.) is a high risk area for breast cancer (Gray et
  Ti
al., 1979). A correlation between height/weight and obesity and breast 
cancer incidence has been shown in different countrieSj.with great variation 
in incidence. This makes it probable that these factors would be relevant 
in the U.K. also.
There have been several studies on the correlation between per capita 
fat intake in countries or regions and breast cancer incidence or mortality^ 
have demonstrated a significant relationship (Drasar and Irving, 1973 
; Armstrong and Doll, 1975 ; Gray et al., 1979). The correlations with total 
fat appeared in most instances to be greater than that with protein or a 
specific type of fat. A study in Hawaii found a relationship between 
individual fat consumption ascertained at interview and incidence of breast 
cancer in different ethnic groups (Kolonel et al., 1981). Three case-control 
studies have also found higher consumption of fat in breast cancer patients 
than in controls (Phillips, 1975 ; Miller et al., 1978 ; Lubin et al., 1981). It 
has also been known for some time that patients who develop breast cancer 
tend to be taller and heavier than those who do not (de Waard, 1975).
Hill et al., (1971a) observed that people in 'Western' countries living on 
diets high in fat and animal protein? excreted greater concentrations of 
faecal steroids than people'from African and Eastern countries. In a 
further study Hill and co-workers (1971b) proposed that gut bacteria may be 
involved in the aetiology of breast cancer. This suggestion is based on 
evidence that intestinal bacteria are capable of converting bile acids and 
cholesterol derivatives to steroidal oestrogens. Since the intestinal flora 
can be altered by diet this offers a possible explanation for the observed 
correlations between diet and incidence of breast cancer. The importance 
attached to the high fat content of the diet was questioned on 
epidemiological grounds by Walker (1971) who also pointed out that 
ingestion of high-fat low-residue diets does not necessarily lead to 
increased excretion of faecal steroids. If  carcinogenic substances are 
present in the intestinal contents, the potential hazard may be increased by 
the slower transit of intestinal contents observed with refined diets of low 
fibre content (Burkitt et al., 1972). However, Drasar and Irving (1973) 
analysed data from 37 different countries and found no correlation between 
dietary fibre and either cancer of the colon or breast cancer, whereas 
dietary fat and animal protein each showed a strong correlation.
A number of metabolic studies in man have demonstrated that a high
dietary intake of saturated fats is associated with raised serum cholesterol
levels (McNamara, 1982). It therefore seemed possible that the result of
the measurements of blood lipids in the present study has provided an
evidence in support of a link between fat intake and breast cancer. There
are a number oflpossible other reasons for raised plasma levels observed in 
■fc
the present stud^. hese include mobilisation of lipid stores for use as a 
source of energy in the cachectic patients (Theologides, 1977). However, 
all our patients had early disease and showed no clinical evidence of
malnutrition. All the blood samples were obtained under baseline 
conditions after an overnight fast for at least 14 hours, so that an 
immediate dietary effect could be excluded. Moreover, the blood samples 
were taken before treatment and probably represented the plasma levels at 
the time of diagnosis.
However, more definite evidence of the link between dietary fat and 
breast cancer is at present lacking and would, indeed, be difficult to obtain 
in patients. One clear problem is the time lapse between the initial 
cancerous change and the clinical presentation, and the difficulty of 
obtaining reliable dietary data relating to.the time when the initial changes 
occurred. This difficulty might be overcdm^by prescribing a low fat diet 
for a sufficient number of women to test the nutritional hypothesis of 
breast cancer aetiology in a prospective survey that necessarily has to be 
carried out for at least a decade.
The plasma lipids of the patients iv\ Hv\I5 SUu\vj_ were modified by 
surgery, since all the patients investigated were treated surgically. 
Immediately after surgery in the cancer patients there was a fall in the 
plasma concentrations of total lipids, phospholipids, cholesterol and 8- 
lipoproteins. This change was simply part of a general postoperative 
response to trauma. In severely injured patients, fat is utilized shortly 
after the accident and often well into 'flow1 phase, and this use of fat can
continue for some time in severely septic patients (Askanazi et al., 1980).
•Hie 
AMoreover, it  was^iherefore necessary to investigate*postoperative
lipid profile of a group of subjects having a different type of operation*,
the present study clearly indicates that certain aspects of postoperative
response in breast cancer c\\s.s commonlj patients having elective
bw\. oMht. oIIrv Kawd 
orthopaedic surgery, . there were some differences. In the
breast cancer patient the whole plasma cholesterol was reduced
, AUlXlAse of
. ^v'5-trvj by a decrease of the 8-lipoprotein cholesterol; the HDL-
/WowevU/ (K
cholesterol^ was increased. Thus, mastectomy has provided therapeutic
means correction of the plasma lipid disturbances in cancer. Dilman et
al., (1982) have studied the effect of Phen formin and Clofibrate on
therapy of cancer patients. It was demonstrated that treatment with these
drugs o\^r,5 2-7 months result in improvement of ^ immunological
status of breast cancer patients who underwent mastectomy.
Thus, mastectomy and hypolipidaemic drugs may be used in the 
treatment of breast cancej provided p i : they exert some effect on lipid 
metabolism.
or
There is persistence of hyperlipidaemia for months,^even years, 
after radical mastectomy (Dilman et al., 1981). A similar pattern persisted 
up until 28 days following surgery in our patients; It is tempting to suggest 
that high blood levels of lipids in cancer patients reflects a higher risk /
. of developing cancer rather than simply 
being a secondary consequence of the presence of the tumour. This finding 
supports the hypothesis of a genetic predisposition to cancer. Barclay and 
Skipski (1975) reported that HDL is diminished and VLDL is increased^not 
only in cancer patients, but also in healthy subjects from families with a 
history of cancer. Our findings suggest that plasma lipids and lipoprotein 
analysis could be used as a tool for the identification of women with a 
predisposition to breast cancer. This will be particularly so in daughters 
whose mothers have died of breast cancer because there is a familial 
tendency in this disease. Thus, a women with any first-degree relative 
(mother, grandmother, sister, or daughter) who has developed carcinoma of 
the breast is herself at greater risk than a women who had no family 
history of breast cancer (Baum, 1981). It would be very useful to know if 
women who have familial risks do have high blood cholesterol and other 
lipid levels. This in fact, is an area worthy of further investigation.
It  would seem that there are two possible explanations for the high
lod
plasma lipid levels in patients with breast cancer^ they dietary*,
-  v or of hormonal origin. Hypercholesterolaemia has been associated 
with increased ovarian and andrenocortical steroid synthesis, decreased 
conversion of oestrone to "antioestrogenic" 2-hydroxyoestrone, increased 
conversion of androesteneodione to carcinogenic oestrone and depression of 
immune response (Vorherr, 1980). However, the relevance of each of these 
mechanisms to the risk of breast cancer is not clear, despite many 
epidemiological, endocrinological and immunological studies in man and 
laboratory animals. It is possible that a high dietary fat level may increase 
susceptibility of mammary tumours to a hormonal growth stimulation. This 
concept is supported by the observations that diets deficient or low in 
dietary fat cause significant reduction in prolactin receptors in the normal 
and neoplastic rodent mammary gland (Cave s Erickson-Lucas, 1982). The 
mammotropic effects of prolactin may be mediated by release of lipids 
from adjacent stromal cells (e.g., adipocytes) or blood. Thus, our 
comparative studies of prolactin and lipid profiles suggest that much can 
be learned, from similar studies in women in developed countries^where 
there was increased association between dietary fat and breast cancer.
The present study supports the theory of an aetiological relationship
between hyperprolactinaemia and breast cancer. In a prospective study of
plasma prolactin levels and subsequent risk of breast cancer, Kwa et al.,
(1981) have reported that in postmenopausal women who developed breast
cancer, the prolactin levels are significantly elevated.being above or at the
virBi J
70th percentile compared the controls. In this study* the results are
consistent with prolactin acting as a late stage tumour promoter. In
another study (Bird et al., 1981) reported that the mean prolactin levels
were significantly higher for postmenopausal women with breast cancer 
w tf h
compared women of similar menopausal status. Concentrations of 
prolactin, oestrogen, and triglycerides were significantly higher in ductal 
fluid than in plasma, but there was little  difference with cholesterol 
concentration (Wynder and Hill, 1977). The high concentrations of prolactin 
and oestrogen found in ductal fluid of Western women may be relevant to 
the development of breast cancer. It would be interesting to know if
uj oulc|
dietary modifications in Western women influence the lipids and other 
hormonal constituents of ; breast fluid. This possibility is worthy of 
further investigation.
It is of interest that this study has shown that plasma lipids were 
higher in postmenopausal cancer than in premenopausal patients, and also 
plasma lipids were well correlated with prolactin in the postmenopausal 
patients. Thus, breast carcinoma in premenopausal and postmenopausal 
seems to be different diseases. De Waard (1975) has drawn attention to the 
concept that there were 2  aetiological types of breast cancer ; one mainly 
restricted to reproductive life in which ovarian factors are present, the 
other type being more prevalent at menopausal and postmenopausal age, in 
which hormonal factors related to overnutrition play a role. In the present 
study, postmenopausal cancer patients have high body weight ie., 6 6  kgo'*
compared to 60 kg in the premenopausal patients, and this is supported by 
the evidence that overnutrition is related to increased incidence of breast 
cancer (De Waard, 1975).
The most important factor in a study of plasma lipids is the age of
the subjects. In women with intact ovaries^ serum cholesterol levels
increase with age (Reitsma, 1979). In the present study, cancer patients
were carefuly matched according to age with the non-cancer patients. A
further control on the patients dietary intake background could have been
Wd b^v\
made available if a dietary survey carried out. Although duct
papilloma patients were non-cancerous^ their lipid levels are in some 
respects similar to the cancer patients. Thus, they were excluded from the 
non-cancer patients. Duct papilloma patients were on average post­
menopausal (with a mean age of 54 years), so this may explain their
relatively high lipid values. An attempt was carried out to overcome this
UlVtil
difficulty by matching^according to age^each patient with cancer 
a.
non-cancer patient. In the present investigation regardless of the 
histopathology of the canceijL the plasma total lipids were found to
be higher in the postmenopausal than in the premenopausal patient.
The finding in breast cancer patients are of some possible clinical 
importance. The possibility that the lipid profile of women attending a 
Screening Centre might be a useful tool in identification of women at risk,
- ' therefore worthy of closer .. Such an approach detects
metabolic disorders which are characteristic of cancer as components of 
the syndrome of cancerophilia. The evidence presented in this 
investigation suggests the possibility of using dietary and pharmacological 
means of correction of lipid metabolism in cancer prophylaxis and therapy. 
The evaluation of such treatment of cancer should be worthy of further 
investigations. Another aspect of clinical importance is the possibility that 
reduction of high levels of lipids in the blood of women who had breast 
cancer will slow down, delay,^reduce, the risk of metastatic spread of the 
disease  ^there appears to be some relationship between lipid components
and degree of breast disease. Patients with advanced breast disease had a 
marginally higher mean plasma lipid concentration than those with early 
breast cancer (Basu and Williams, 1975). In patients with breast cancer 
followed for several years, those who had more normal values for HDl_ 2  
when first examined, made more satisfactory responses to mastectomy 
p r o c e d u r e s , m a i n t a i n e d  higher serum levels of HDL? during the 
postoperative period  ^ L T '7 '
—_ (Barclay et al., 1959).
It was interesting to note that^kfter surgery 4n some patients1, the
was
whole plasma cholesterol was reduced predominant decrease^in 3 -
lipoproteins, but the HDL-cholesterol was increased. This negative 
relationsip between 3-lipoproteins and HDL-cholesterol may be a 
protective factor 7 -  development of deep-vein thrombosis (DVT). 
Lipoproteins have been been implicated in the clotting process, especially 
in relation to their possible role in formation of atherosclerotic plaques and 
thrombi. Antiplasmin activity is associated with both major classes of 
lipoproteins, but predominantly with 3-lipoproteins (Barclay, 1979). There is 
indirect clinical evidence to support the relationship between lipoprotein 
levels and DVT as a postoperative hazard. In African and Eastern 
communities, e.g., in the Sudan, postoperative venous thrombo is rarer 
(Hassan et al., 1973) than in the United Kingdom. The frequency of DVT 
therefore parallels geographical distribution of serum lipid concentrations, 
and of dietary fat. Further information is highly desirable concerning the 
possible association between hyperlipidaemia and venous thrombosis.
It is important to note that breast cancer, the commonest cancer 
among women, is more frequent in higher British social classes (Doyal and 
Epstein, 1983). !^  , believe^ that intervention to reduce risk factors in
the patients at risk of breast cancer is the most rational and potentially 
beneficial therapy available.lt IS recommend that dietary modifications as 
a possible preventive measure for breast cancer should be carried out 
among rich families. All women who are observed prospectively for breast 
cancer should have measurement of dietary intakes, body fatness and 
hormonal and lipid levels, at regular intervals. Ideally such studies should 
consider population of girls atj,age of menarche and^early reproductive 
years, since hormone profiles are probably established at that period. 
Breast cancer is much less prevalent throughout East Africa than in the 
Sudan (Burkitt, 1967). It would be worth carrying out a case control study 
in the Sudan to find out whether similar relationships between breast 
cancer and blood lipids exist. A further comparison between the frequency 
of hyperprolactinaemia in breast cancer in the Sudan and the United 
Kingdom may provide clues concerning causation of mammary 
carcinogenesis.
A greater understanding of lipid metabolism in breast cancer
S^ Y\/ecl.
patients may be well ’ by further studies in erythrocyte lipid 
membranes. This, of course, is of interest because these people who 
believe that cancer is caused by an abnormality in cell membranes which 
permit entry of carcinogens since polynsaturated fatty acides (PUFA) are 
converted by free radical reactions to lipid peroxides, a model involving 
breast cancer and lipid peroxidation has been advanced (Hopkins and West, 
1976). It is possible that increased peroxidation of membrane lipids results 
in alterations in the function of transformed mammary cell membranes 
which, in turn, permits increased rates of growth (Hopkins and West, 1976).
cwre. re*<ar/e4 to  ' ° <L' Ccx^Vl<1^  ° a^
Further investigations^on the nature of plasma free fatty acids (FFA)
associated with elevated plasma cholesterol to find out whether these FFA
are partly due to esterified cholesterol. Until such studies have been
carried out and their observations confirmed, recommendations for major
dietary modifications as a possible preventive measure for breast cancer
are clearly premature. Those engaged in attempting to prevent breast
cancer will not have succeeded until the incidence of breast cancer is
actually reduced. To realize this possibility requires greater attention and
more inter-disciplinary activity than we have given to the field of breast
cancer aetiology so far.
6.2 Conclusions
The results of the present study agree with some of the work already 
carried out on the assocation of dietary fat and breast cancer. The findings 
suggest that dietary fat intake, if related to increased breast cancer risk is 
related through an abnormality in lipid metabolism. Development in the 
diagnosis of early disease and in methods of lipid analysis have coincided 
with an urgent need to investigate possible aetiological factors. Human 
breast cancer is probably of multifactorial aetiology and the present 
findings would be in agreement with an involvement of dietary fat.
The abnormal prolactin pattern in the present study may indicate 
some relationships between prolactin and breast carcinogenesis. The 
occurrence of increased prolactin levels in cancer patients, coupled with 
the finding of a correlation between prolactin and some lipid profiles, does 
constitute further evidence for the hypothesis that prolactin is an 
important determinant of breast cancer risk. However, the present data
also provides a basis for further exploration of the role of prolactin in the
by
aetiology of breast cancer, either directly as a carcinogen^as a promoter, 
or indirectly through some more metabolic process. The findings described 
in this thesis have added a further fact to our understanding of metabolic 
derangements in cancer patients.
It has been known for some years that protein metabolism is altered 
due to trauma; the present study has shown that plasma lipids are also 
affected. The marked fall in plasma beta-lipoproteins and cholesterol was 
associated with trauma regardless of the pathological state of patients.
These findings suggest that injury is an important factor in the fall of
p Y'<L\jioUS\vj
plasma 3 -lipoproteins and cholesterol^found by those who have 
investigated the effects of trauma, myocardial infarc tion and
postoperative changes. The changes in 3-lipoproteins may be used as a
o f
mean/monitoring the clinical response of patients undergoing surgical 
treatment. The present study strongly suggests that the values for plasma 
lipids and lipoproteins in the immediate postoperative period and 
convalescence are not representative of pre-traumatic levels in the 
patients. For this reason patients who are being investigated for 
hyperlipidaemia should have blood samples taken at lest 8  weeks after an 
injury such as myocardial infarction or surgery.
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APPENDICES
APPENDIX I
D E T A I L S  O F  P A T I E N T S  I N  T H E  BREAST D I S E A S E  STUDY
Case Age 
(yea r s )
We i gh t  
(kg)
Di agnos i s T rea tmen t
1 50 64 Adenoca rc i noma L e f t  Patey mastectomy & 
cyclophosphami  de
2 42 53 Adenoca rc i noma Ri ght  Patey mastectomy & 
cycl ophosphami de
3 57 6 2 Adenoca rc i noma Ri ght  Patey mastectomy & 
cycl ophosphami de
4 51 58 Adenoca rc i noma L e f t  wi de l oca l  e x c i s i o n  & 
a x i l l a r y  t a i l  c l e a r a n c e  & 
cycl ophosphami de
5 30 65 Adenoca rc inoma 
& l ymphat i c  
me tas tas i s
Ri ght  a x i l l a r y  c l e a r a n c e  & 
l e f t  oophrectomy and 
cycl ophosphami de
6 40 52 Poor l y  d i f f e r e n t ­
i a t e d  adeno­
ca rc i noma
A x i l l a r y  b l ock  d i s s e c t i o n
7 52 58 Invas i ve d u c t a 1 
ca rc i noma
Ri ght  Patey mastectomy
8 56 63 1 nvas i ve duct a l  
ca rc i noma
Exc i s i onal  bi opsy
9 54 65 Tu bu l a r  ca rc i no­
ma & f i b  ro-  
adenoma
E x c i s i o n a l  bi opsy & r i g h t  
patey mastectomy & c y c l o ­
phosphami de
1 0 42 6 0 Poo r l y  d i f f e r e n t -  
i a ted i n v a s i v e  
duct a l  ca rc i noma 
& ax i 1 1  a ry lymph 
nodes me t a s t a s i s
Patey mastectomy
1 1 50 50 Poo r l y  d i f f e  ren t -  
i a t e d  adeno-  
carcinoma & venous 
& 1 ympha t i c 
i nvas i on
L e f t  Patey mastectomy & 
cycl ophosphami de
1 2 45 65 ' Adenoca r c i  noma Patey mastectomy
13 47 67 Poor 1y d i f f e r e n t -  
i a ted i nvas i ve 
duct a l  ca rc i noma
Ri ght  Fbtey mastectomy S 
tamox i fen
14 52 63 M u l t i p l e  ca rc i noma Ri ght  wide l oca l  mastectomy
15 46 63 E x t e ns i ve  i n v a s i v e  
l o b u l a r  c a r c i  noma
Radi cal  mastectomy o f  l e f t  
b r e a s t  and cycl ophosphami de
1 6 45 65 Wel l  d i f f e r e n t ­
i a t e d  t u b u l a r  
ca rc i noma
Radi cal  mastectomy o f  l e f t  
b r e a s t  S cycl ophosphami de
■ ase age
( y e ar s )
weignu 
(kg)
u i agnos i s i r ea  tme n t
17 40 48 M u l t  i p 1e q uadr ant  
in s i t u  duct a l  & 
l o b u l a r  ca rc i noma 
& lymph node 
me tas tas is
L e f t  r a d i c a l  mastectomy & 
tamoxi  fen
1 8 38 44 1 nvas i ve duct a l  
ca rc inoma
L e f t  Patey r a d i c a l  ma s t e c t ­
omy & cycl ophosphami de & 
tamoxi  fen
19 52 54 In s i t u  d u c t a 1 
ca rc i noma
Ri ght  a t e y  mastectomy
2 0 .48 6 1 1 nvas i ve d u c t a 1 
ca rc i noma
L e f t  Patey mastectomy & 
tamoxi  fen
2 1 47 55 Invas i ve duct a l  
ca rc i noma
L e f t  subcutaneous  
mastectomy
2 2 50 64 1 nvas i ve d u c t a 1 
ca rc i noma & in  
s i t u  ca rc i noma
P a r t i a l  mastectomy r i g h t  
o u t e r  h a l f  & b l ock  d i s s e c t -  
i on & tamoxi  fen
23 46 54 In s i t u  ca rc i noma Ri ght  subcutaneous  
mastectomy
24 48 55 L e f t  b reas t 1obu-  
1 a r hype r p 1 as i a
Ex c i s i on  o f  l e f t  a x i l l a r y  
t a i l
25 59 49 P a n i c u l i t i s Ex c i s i o n  o f  r i g h t  b r e a s t  
1 ump
2 6 56 58 Duct e c t a s i a E x c i s i o n a l  b i opsy o f  l e f t  
b r e a s t
27 65 ‘ 6 1 Le f t  b reas t 1ump Ex c i s i on  o f  l e f t  b r e a s t  
1 ump
2 8 51 6 2 Benign 1 i poma 
( l e f t  b r e a s t )
Ex c i s i on  o f  a 1ump
29 6 0 55 Duct me tap 1 as i a Local  e x c i s i o n a l  bi opsy
30 52 67 Fib roadenoma Ex c i s i on  o f  a lump ( r i g h t )
31 44 6 1 F i b roadenoma Ex c i s i on  o f  a lump ( l e f t )
32 30 58 Fi b roadenoma E x c i s i on  o f  lump ( r i g h t )
33 65 59 S c l e r o s i n g  f i b r o -  
adenoma
E x c i s i o n  o f  a lump ( l e f t )
3k 56 65 Benign c a l c i f i e d  
f ibroadenoma
L o c a l i s a t i o n  & e x c i s i o n  o f  
b reas t 1 ump
35 48 '■ 6  3 Duct pap i 11oma Mi crodectomy ( l e f t  b r e a s t )
36 73 70 Duct pa p i l l o ma L e f t  microdectomy
37 48 78 Duct pap i 11oma Ri ght  microdectomy
38 48 6 0 Duct pap i 11oma M i c rodec tomy
39 27 63 B i l a t e r a l  f i b  r o ­
adenoma
Lump exc i s i on
40 50 49 F i b roadenoma Ex c i s i on  o f  mass ( r i g h t )
Case Age 
(yea r s )
Wei ght  
(kg)
• D i agnosi  s T r eat ment
41 24 54 L e f t  f i broadenoma Exc i s i on o f  a 1 ump
42 33 56 Ri ght  f i b  r o ­
adenoma
Ex c i s i on  o f  r i g h t  lump
43 49 69 Beni gn mammary 
d y s p l a s i a
Biopsy o f  r i g h t  b r e a s t
44 39 55 Duct cyst Exc i s i on  o f  duct  cyst
45 54 65 Fi b ros i ng adeno­
s i s
L o c a l i s a t i o n ^  bi opsy  
( r i g h t )
46 6 2 69 L i poma ( r i g h t  
b r e a s t )
E x c i s i on
47 43 40 Benign mamma ry 
d y s p l a s i a
E x c i s i on
48 31 54 Ch ron i c i n f 1am- 
ma to ry ce 1 1 
i n f i l t r a t i o n
Ex c i s i on
49 42 6 8 1 n te r 1 ob u 1 a r 
s c 1 e ros is
Ri ght  b r e a s t  lumpectomy
50 43 51 P e r i l o b u l a r  
f  i b ros i s
E x c i s i on
51 38 55 Schirrous Adeno­
carcinoma Left Patey Mastectomy
52 47 67 B reas t ca rc inoma Patey mastectomy
53
54
42
42
6 0
6 1
Poor l y  d i f f e r e n t i a t e d  Subcutaneous mastectomy 
jian t ce 1 1  ca rc i noma + "tamoxi fen
Adenocarcinoma " Patey mastectomy + y
Cyclophosphamide & i camoxi fe
55
56
47
41
64
83
I n v a s i v e  duct  
carcinoma
Foca1 1 ns i tu Duct  
Ca rc i noma
L e f t  Patey mastectomy  
mas tectomy
57 47 56 Adeno carcinoma L e f t  Hemimas tectomy
58 33 64 1 nvas i ve duct  
ca rc i noma
L e f t  subcutaneous mastectom
53 40 65 1 nvas i ve duct  
ca rc inoma
Ri ght  Patey mastectomy
60 56 A d e n o  c a  r c  i n o m a W i d e  e x c i s i o n  ( m e d i a l  
q u a d r a n t )  l e f t  b r e a s t
C a s e
61
6 2
63
64
65
66
67
68
69
70
71
72
73
T r e a t m e n t
Ri ght  Pat ey  mastectomy
Wide l o c a l  e x c i s i o n ,  l e f t  
b r e a s t
Patey mastectomy
58 60 I n v a s i v e  duct  Ri ght  Patey mastectomy
ca rc i noma
55 121 I n v a s i v e  duct  R i g h t b r e a s t  wide
carci noma l oca l  e x c i s i o n
72 51 Poor l y  Patey mastectomy
di f f e r e n t  i a t ed  
i n v a s i v e  duct  
ca rc i noma
58 55 Br east  carci noma L e f t  Patey mastectomy
59 73 Br east  carcinoma L e f t  wi de l o c a l  e x c i s i o n
Poor l y  d i f f e r e n t i a t e d  
i n v a s i v e  duct
carcinoma Ri ght  Patey mastectomy
Minimal  Ri ght  Pat ey  mastectomy +
i n v a s i v e  cycl ophosphami de ,
ca rc inoma
73 56 Adenocarcinoma Wide l o c a l  e x c i s i o n  ( l e f t )
6 3  7k Invasive!  duct  Wide l oca l  e x c i s i o n  ( l e f t )
ca rc i noma
58 7 8  Wel l  Wide l oca l  l e f t  b r e a s t
d i f f e r e n t i a t e d  e x c i s i o n
i nvas i ve 
ca rc i noma
5k 59
61 58
Age Wei ght  Di agnosi s
( y ea r s )  (kg)
6 7  60 I n s i t u d u c t a l
ca rc i noma
73 57 Adeno id cyst
ca rc i noma
53 81 Poo r 1y
d i f f e  r ent  i a t ed  
i n t r a d u c t  
ca rc i noma
61 63 Invas i ve duct  
ca rc i noma
Ri ght  Patey mastectomy
Case Age
(yea r s )
We i gh t
( k g) .
75 36 52
76 55 64
77 6’5 75
78 24 49
79 k5 66
80 37 61
81 46 69
82 25 70
83 . 60 64
8 4 51 65
85 48 85
86 26 60
87 65 55
88 43 52
89 6? 54
90 56 67
91 62 79
92 85 58
93 46 56
T reatmen t
Exc i s i on
Exc i s ion
Exc i s ion
Exc is ion
Exc i s ion
Exc i s i on
Exc i s ion
Exc i s i on
Microdectomy  
Microdectomy  
L e f t  microdectomy
Di a g n o s i s
Ftbroadenoma
F i b roa denoma
Fi broadenoma
Fibroadenoma
Fi b roadenoma
Fi broadenoma
Fi b roadenoma
Fi b roadenoma
Duct pap i 11oma
Duct pap i 11oma
Duct pap i 11oma
I n t e r l o b u l a r  
scl  e ros is (. )
Adenos i s
Focal  f i b r o s i n g  
adenos i s
Duct adenosi s
F a t t y  b r eas t  
t i s s u e
Breast  scar  
1 ump
Benign mammary 
dys p 1 as i a
M i c rocys t i c 
d i sease
Exc i s i on
Loca1 i za t ion 
b i opsy
L o c a l i z a t i o n  
bi opsy
L o c a l i z a t i o n
bi opsy
S ubc i rc u 1 a r 
l e f t  b r e a s t
6 exc i s i o n a 1
and e x c i s i o n a
and exc i s i ona
exc i s i on o f
Loca1 i za t i on and 
e x c i s i o n a l  bi opsy
Exc i s i o n a 1 bi opsy  
( . l e f t  b r e a s t )
L o c a l i z a t i o n  and 
e x c i s i o n a l  b i opsy
a s e
94
95
96
97
98
99
Age Weight  Di agnosi s
(yea rs)  (kg)
5 7 6 0 F i b r o 1 ipoma
57 56 B reas t duct
cyst
52 52 Li poma
45 59 F i br oa de nos i s
70 65 F i br oa de nos i s
6 3  6 7  Fi broa'denos i s
T r e a  t m e n  t
L o c a l i z a t i o n  and bi opsy
E x c i s ion
L o c a l i z a t i o n  and E x c i s i o n a l  
b i opsy
Ex i s i o n  o f  l e f t  b r e a s t  
1 ump
Ex c i s i o n  o f  l e f t  b r e a s t  
1 ump
Ex c i s i on  o f  r i g h t  b r e a s t  
1 ump
A P P E N D I X  I I  
D e t a i l s  o f  P a t i e n t s  i n  t h e  O r t h o p a e d i c  S t u d y
C a s e  A g e  S e x  D i a g n o s i s  O p e r a t i o n
1 70 M Subcapital Austin Moore
2 97 F
3 67 F Subcapital Austin Moore
4 84 F Subcapital Austin Moore
5 85 F In tertrochanteric  Pin
6 79 F In tertrochanteric  Pin and Plate
7 77 M Subcapital Austin Moore
8 91 F In tertrochanteric  Pin and Plate
9 80 F In tertrochanteric  Pin and Plate
10 94 F Subcapital Austin Moore
11 84 F Intertrochanteric Pin and Plate
12 8 7  M Subcapital Austin Moore
13 8 7  F Subcaptial Austin Moore
14 8 7  F In tertrochanteric  Pin and Plate
15 81 F Subtrochanteric Pin and Plate
16 69 M In tertrochanteric  Pin and Plate
17 90 F Subcapital Austin Moore
18 73 F Subcapital Austin Moore
19 70 M -  Hip replacement
20 6 5  M -  Hip replacement
21 100 F -  Hip replacement
22 68 F -  Hip replacement
23 57 F -  Hip replacement
24 75 F -  Hip replacement
25 80 F - Hip replacement
26 8 3  M -  Hip replacement
27 80 F -  Hip replacement
